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Tuberculosis (TB) continues to be the leading cause of death from a single infectious agent worldwide. 
The rapid emergence of multidrug-resistant and extremely drug-resistant underpin the urgent need 
for novel, safe and efficacious drugs. D-Cycloserine (DCS) is an oral bacteriostatic anti-tubercular drug 
used for the treatment of drug-resistant TB. Despite attractive properties, DCS displays significant 
toxicity at effective dosages. However, a synthetic analogue of DCS, terizidone, has shown an improved 
safety profile.  
This study focused on the synthesis of two new classes of DCS analogues: isoxazolidin-3-one-imines 
(ISIs) and 3-isoxazolidin-4-yl amides (ISAs). These analogues were designed to act as potential 
prodrugs. In an effort to explore structure-activity-relationships, a total of 17 compounds were 
synthesized, fully characterized, and evaluated in vitro for their antimycobacterial activity against the 
drug-susceptible Mtb H37Rv strain cultured in 7H9/ADC media.  Of these, two compounds displayed 
noteworthy antimycobacterial activity (MIC99 ≤ 10 μM). In addition to this, all 17 compounds 
manifested low cytotoxicity (IC50 > 25 μM) when tested in vitro against the chinese hamster ovarian 
cells and the human hepatocytes cells. Furthermore, a selected potent compound displayed high 
microsomal metabolic stability in rat, mouse and human liver microsomes. 
The kinetic solubility of the target compounds was determined using a HPLC-based method. The 
solubility data obtained was then correlated with melting point, tPSA and cLogP in order to establish 
structure-solubility relationships across the two compounds series.  Solubility was strongly correlated to 
melting point in the IZAs series (R2 = 0.9318) and moderately correlated to tPSA for IZIs (R2 = 0.164, whereas 
there was no correlation between solubility and cLogP (lipophilicity) in either class of compounds (R2 = 
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Chapter 1: Introduction and literature review 
 
1.1 Chapter overview 
This chapter provides an overview of tuberculosis (TB) and its current treatment, including its 
epidemiology, transmission, pathogenesis, challenges associated with current chemotherapy, as well 
as advances made in anti-TB drug discovery and development. In addition, D-cycloserine (DCS) and its 
structural derivative terizidone are discussed as these structural motifs form the basis of this work as 
potential scaffolds for anti-TB drug discovery. Lastly, a research program is presented, and the 
rationale, hypothesis, and specific aims are stated. 
 
1.2 Epidemiology of TB 
Tuberculosis (TB) is one of the oldest and deadliest infectious diseases plaguing mankind.1,2 Its 
causative agent in humans is the airborne bacterium Mycobacterium tuberculosis (Mtb). Among 
infectious diseases, TB remains a global pandemic as it is the leading cause of death from a single 
infectious agent worldwide, competing with human immunodeficiency virus (HIV).3,4 According to the 
World Health Organization (WHO), one third of the world’s population is infected with Mtb and 10 
million people developed TB in 2018 with 1.4 million deaths globally (Figure 1.1).4 
Figure 1.1: Estimated global tuberculosis (TB) incidence rates for 20184 
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TB is the leading cause of death amongst TB/HIV co-infected patients worldwide, accounting for more 
than 0.4 million cases and 0.37 million deaths in 2018 (Figure 1.2).3,4 Such cases of co-infection may 
occur in patients previously immune-compromised as a result of other epidemics such as HIV and 
diabetes, consequently increasing their risk of developing TB.3,4 Although TB is a global concern, its 
geographical distribution is disproportionate as 87% of TB-related deaths were reported in developing 
countries, with countries in Asia (India, Indonesia, China, Philippines, and Pakistan) and Africa (Nigeria 
and South Africa) being the most affected.4 
 
Figure 1.2: Estimated human immunodeficiency virus (HIV) prevalence in new and relapse tuberculosis 
(TB) cases in 20184 
 
1.3 Transmission and pathogenesis 
TB is a communicable disease that is transmitted through coughing and sneezing by means of aerosols 
carrying infectious bacilli. Upon inhalation of these air droplets, the pathogen reaches the alveoli in 
the lungs, which is the primary site of infection (pulmonary TB).4-6 It is from this point that bacteria 
may enter the bloodstream and infect other sites such as the lymphatic and genitourinary systems, 
bones and joints to cause extrapulmonary TB.1 In the alveoli, Mtb bacilli are engulfed by the main 
phagocytic cells known as macrophages. These are prime defence cells against microbial intruders 
(Figure 1.3).6 Infected macrophages induce a localized pro-inflammatory response to Mtb, and 
phagosome maturation takes place to eradicate the bacterial infection. However, Mtb has developed 
mechanisms to escape and survive within macrophages, thus differing from other mycobacterial 
infections.1,6-7 Dendritic cells which are an important mediator between the innate and adaptive 
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immune response, also take up mycobacteria and mycobacterial fragments and can engulf 
mycobacterial antigens via receptor-mediated phagocytosis. Upon activation, dendritic cells migrate 
to the draining lymph nodes and prime naïve T cells (CD4+ & CD8+). This results in effector T-cells 
(CD+4, CD+8 and Regulatory T cells) migrating back to the site of infection in the lungs, and in 



















Figure 1.3: Transmission and pathology of tuberculosis (TB)1 
 
Granulomas comprise concentric layers of infected macrophages in the core, surrounded by foamy 
macrophages (macrophage surrounded by the rim of lymphocytes and by a coat of fibroblast that 
encloses it) and foamy giant cells as well as activated T and B cells (Figure 1.3).1,6 In 90% of cases, this 
interplay between the innate and adaptive immune responses serves to control the infection, but the 
patient will remain latently infected and thus at risk of reactivation.6 However, in 10% of cases, the 
mycobacteria proliferate, resulting in the reduction and impaired function of CD4+ cells causing 
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macrophages to degrade and granulomas to become necrotic, thus resulting in the release of bacteria 
into the extracellular medium.6,7   
In an immunocompetent individual, latent TB infection (LTBI) may persist for decades with no clinical 
symptoms of active TB.1,6 However, during immunosuppression, Mtb may become metabolically 
active. There are approximately 2 billion people infected with LTBI who are therefore at risk of disease 
reactivation.1,6 Children under the age of 5 years, the elderly, individuals recently exposed to active TB 
(recent contact of <2 years), those living in over-crowded places, who are being treated with 
immunosuppressants, or are HIV-positive are at a high risk of developing active TB. This includes 
individuals with silicosis, chronic renal failure, and those that are malnourished.1,4,9 The symptoms of 
active TB include weight loss, poor appetite, night sweats, fever, productive or dry cough, and chest 
pain.4  
 
1.4 Etiology of TB 
TB is characterized as an aerobic, slow-growing, immobile, non-sporulating, weakly gram-positive, and 
acid-fast bacillus. As the Latin name suggests, the bacilli are slightly curved or straight rod-shaped 












Figure 1.4: Scanning electron micrograph of Mycobacterium tuberculosis10 
 
 
TB may also be caused in humans and animals by several other mycobacterial species, including 
Mycobacterium bovis, Mycobacterium africanum, Mycobacterium microti, and Mycobacterium 
canetti, which are collectively known as the mycobacterium complex.11 Mycobacteria are thought to 
have originated from soil-dwelling ancestors and evolved as pathogens to both human and animal 
hosts during the domestication of animals 10 000 years ago.1 Mtb is an extremely successful pathogen 
that has co-evolved with humans as specific hosts for thousands of years. This distinctive relationship 
19 
 
has uniquely shaped the mycobacterial genome to encode mechanisms that allow the bacilli to resist 
attack and elimination by the human immune system.12 Mtb’s cell wall is unique in comparison to 
other prokaryotes as it comprises a G+C-rich genome, a distinctive structure composed of lipids, 
proteins, and carbohydrates, which are key for its survival. The cell wall is composed of 
peptidoglycans, arabinogalactans, and mycolic acids that are surrounded by a non-covalently linked 
outer capsule of proteins and polysaccharides (Figure 1.5).13,14 This cell envelope is critical for the 
mycobacterium’s physiology as numerous crucial processes occur in this compartment. These include 
the protection of bacterial cells from hostile environments, mechanical resistance of cells, transport 

















Figure 1.5: The mycobacterial cell wall, composed of three distinct macromolecules12  
NAM, N-acetylmuramic acid; NAG, N-acetylglucosamine; DAP, diaminopimelic acid. 
 
The hallmark of Mtb is its unusual abundance of lipids, which constitute 40% of the dry weight of the 
cell wall and include the exceptionally long-chain α-branched saturated fatty acids known as mycolic 
acids.14 The mycolic acids are responsible for Mtb’s unusually thick waxy cell wall, whose unique 
characteristics such as acid-fastness against staining, hydrophobicity, resistance to drying, and 
resistance to varying acid/alkaline environments enable survival in its host.4  
Lipids have been implicated in many of the biological properties of mycobacteria, as both structural 
and virulence factors that activate or supress the immune response.11 For example, lipids may serve 
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as receptors for the invasion of macrophages and dendritic cells, prevent phagolysosome maturation 
enabling Mtb to survive within the macrophages, and mask pathogen-associated molecular patterns 
(PAMPS) on the cell to avoid toll-like receptor evading innate immunity. Lipids play a key role in 
enlisting proinflammatory cytokines that stimulate granuloma formation. Lastly, lipids enable Mtb to 
escape the adaptive immune response of the host by dendritic cell maturation and T-cell activation.12 
Evidently, the remarkable success of Mtb as a human pathogen requires a sophisticated programme 
for control of host immune responses by the bacilli. In addition, and considering the evolutionary 
history of the Mtb genome, it is not surprising that immune evasion programmes expressed by this 
organism interfere with many of the known host innate and adaptive immune response pathways.12 
As Mtb remains a global public health concern, developing a more comprehensive understanding of 
immune evasion remains key in the quest for more effective vaccines and treatments for TB. 
 
1.5 Anti-TB chemotherapy 
Anti-TB chemotherapy development began in the 1940s with the discovery of streptomycin (STR) and 
para-aminosalicylic acid (PAS; Figure 1.6). Although it was effective in the short term, STR 
monotherapy was discontinued as many patients developed STR-resistant TB or experienced serious 
side effects such as loss of hearing.3,5 Simultaneously, PAS was identified as a bacteriostatic agent 
against Mtb, including STR-resistant strains, and was able to prevent the development of STR 
resistance. PAS monotherapy was also shown to be effective against pulmonary TB.8,11 Unfortunately, 
PAS resistance also developed, and the drug was poorly tolerated in patients leading to 
gastrointestinal side effects and occasional hepatitis. By the end of the 1940s, the standard treatment 
for TB was STR-PAS combined therapy, thus driving the shift from conventional monotherapies to 
novel combination therapy.8,11  
When isoniazid (INH; Figure 1.6) was discovered in the 1950s, its anti-tubercular bactericidal activity 
was found to be more effective as part of combination treatment with STR and PAS than when 
administrated alone. This led to standardization of the first combination chemotherapy regimen. This 
triple drug therapy was shown to prevent the development of resistance to STR, INH, and PAS, and 
the entire course of treatment was extended to 18-24 months.3,16 Several other antitubercular agents 
were discovered and developed in the 1950s, including pyrazinamide (PZA), cycloserine, ethionamide, 
prothionamide, and kanamycin (Figure 1.6). These drugs were originally only used in patients who did 
not respond to standard therapy, as these were thought to be inferior to the triple drug combination-
based therapy.3,17  
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In the 1960s, the introduction of rifampicin (RIF; Figure 1.6) revolutionized anti-TB therapy as it 
shortened treatment from 18 to 9 months without increasing the relapse rate.17 In addition, 
reintroducing PZA at a non-toxic, lower dosage than that previously used paved the way for the 
current, widely used regimen.3,17   
 
 
Figure 1.6: TB drugs introduced in 1940s, 1950s, and 1960s 
 
1.5.1 Current anti-TB treatment 
Current anti-TB treatment comprises drugs that can be classified according to their efficacy, potency, 
drug-class, and experience of use (Table 1.1). Anti-TB drugs are divided into first-line drugs (Group 1) 
and second-line drugs (Groups 2-5). First-line drugs are used to treat drug-susceptible TB (DS-TB), with 
the exception of STR which is classified as an injectable drug (Group 2), and second-line drugs are used 
for the treatment of drug-resistant TB. These are further divided into groups according to features 
such as cross-resistance.18  
The paramount objectives for TB therapy are to: (i) shorten and simplify treatment for active, drug- 
sensitive TB, (ii) improve the efficacy, safety, and duration of treatment, (iii) improve the safety of 
combination therapy for patients co-infected with TB and other chronic diseases, and (iv) establish an 
effective therapy for LTBI.3  
 
Table 1.1: First-line and second-line anti-TB drugs 
Group Drug type Drugs 
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1 First-line oral agents Isoniazid (INH), rifampicin (RIF), rifapentine, pyrazinamide (PZA), 
ethambutol (ETB), rifabutin 
2 Injectable agents Aminoglycosides: Kanamycin, amikacin, streptomycin (STR), 
Polypeptide: Capreomycin 
3 Fluoroquinolones Levofloxacin, moxifloxacin, ofloxacin, gatifloxacin 
4 Oral bacteriostatic 
second-line agents 
p-Aminosalicylic acid, cycloserine, terizidone, ethionamide, 
prothionamide 
5 Drugs with limited 
efficacy or safety data 
Bedaquiline, delamanid, clofazimine, linezolid, 
Amoxicillin/clavulanate, thioacetazone, meropenem, 
imipenem/cilastatin, clarithromycin 
 
1.5.2 DS-TB therapy 
Approximately 80-95% of patients diagnosed with pulmonary TB are infected with fully drug-
susceptible Mtb strains.4 To ensure optimal treatment of DS-TB and prevention of drug resistance, the 
WHO recommends application of the standardized chemotherapeutic treatment regime termed as 
the Directly Observed Treatment, Short-Course (DOTS; Figure 1.7). The regimen for new DS-TB cases 
under DOTS involves an intensive phase during which INH, RIF, PZA, and ETB are administrated daily 
for 2–4 months. During this phase, the bacilli are killed rapidly, and this is followed by a continuation 
phase to avoid relapse. The continuation phase comprises administration of INH and RIF in 
combination with some second-line drugs (Figure 1.7).8,11,17  
 
Figure 1.7: Summary of the current short anti-TB treatment regimen 
There are three treatment plans available for HIV/TB co-infected patients. These include the 
administration of INH daily for 6 months, INH and RIF daily for 3 months, or INH and RIF twice weekly 
for 3 months.5 However, drawbacks of this combination therapy include toxicity and intolerance, 
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which may lead to treatment interruption and regimen changes, drug-drug interactions with 
antiretrovirals in HIV co-infected patients, and consequent poor patient compliance, which has been 
associated with the development of drug resistance.18 
 
1.5.3 Management of DS-TB  
Although first-line drugs have been instrumental in the successful treatment and prevention of TB, 
drug resistance remains an issue. Drug-resistant TB may be classified as mono-resistant (resistance to 
a single first-line agent), multi-drug resistant (MDR-TB; resistance to INH and RIF), or extensively drug-
resistant (XDR-TB, resistance to INH, RIF, any of the fluoroquinolones, and at least one of the three 
second-line injectable drugs). Strains that are resistant to all available first- and second-line drugs are 
termed totally drug-resistant (TDR-TB).19 
The WHO recommends the use of five second-line drugs for the treatment of MDR-TB (Figure 1.8). 
The choice of drugs is based on susceptibility testing of Mtb against available drugs. In the absence of 
susceptibility results, the choice of the regimen is based on factors such as drug resistance patterns in 
the geographic area, previous drug exposure, presence of underlying medical conditions, and adverse 
effects associated with the drugs. Frequently used regimens include PZA (Figure 1.6), a 
fluoroquinolone, amikacin (Figure 1.8) or kanamycin (Figure 1.6), ethionamide/prothionamide (Figure 
1.6), cycloserine (Figure 1.6), and PAS (Figure 1.6).5,11,20  
Although an M. bovis Bacille Calmette-Guerin (BCG) vaccine is currently available, it is primarily used 
as a protective measure against paediatric TB, and is unfortunately not effective in preventing 






Figure 1.8: Second-Line anti-TB drugs 
 
1.5.4 Present status and development of resistance globally 
Extensive combination therapies were prescribed to limit the risk of developing resistance to every 
new agent, as seen through the history of clinical development of TB drugs. In the 1990s, the rate of 
relapse was high despite the introduction of both short-course chemotherapy and DOTS. This period 
was also marked by increasing numbers of mono- and multidrug-resistant TB cases.8 There are two 
types of drug resistance: primary resistance occurs in a person who has been infected with a resistant 
25 
 
Mtb strain, and secondary resistance develops during therapy either through improper chemotherapy 
use or poor patient compliance relating to side effects from the cocktails of antibiotic therapies.4,8 
Outbreaks of drug-resistant strains (primary infected) occurred as early as the 1970s, and in the 1990s, 
there were numerous MDR-TB outbreaks in patients co-infected with HIV. This may be attributed to 
the fact that no viable treatment for HIV was available during this period, and HIV-positive patients 
were therefore more susceptible to TB infection. The development of MDR-TB in infected patients 
ultimately led to transmission of drug-resistant Mtb, first within institutions and hospitals and 
eventually the community.8,20  
TB drug resistance may be ascribed to mutations that result in a loss of susceptibility to antibiotics. 
For example, INH’s primary target is InhA, which encodes enoyl-ACP-reductase, a key enzyme for the 
production of mycolic acids. INH is a prodrug that requires bioactivation by Mtb catalase (KatG) to 
form an isonicotinic acyl radical.20-22 INH resistance may therefore arise from a variety of mutations 
that can either affect INH activation by KatG, binding of INH to target InhA, or InhA expression. 
However, amino acid substitution at position 315 from serine to threonine (S315T) in KatG results in 
a high level of INH resistance, with full virulence.22 Resistance to RIF may also be observed. This drug 
inhibits RNA polymerase at the level of the β-subunit encoded by the rpoB gene. Resistance to RIF is 
acquired because of a point mutation that is located predominantly in the 511-533 regions of the RpoB 
polypeptide. Approximately 95-98% of RIF resistance mutations are located in the 81-bp segment of 
rpoB.  
Treatment of MDR-, XDR-, and TDR-TB requires the introduction of second-line drugs and use of 
repurposed agents such as fluoroquinolones. Unfortunately, these second-line drugs lack proven 
efficacy in untested combinations. In cases in which first- and second-line agents have failed because 
of extensive resistance, agents from the non-WHO-approved list of third-line agents may be used. 
However, there are minimal data to support the use of third-line agents apart from linezolid whose 
use is limited by toxicity and high cost.8 Consequently, treatment of MDR-TB with poorly active 
second- and third-line drugs has led to the emergence of XDR-TB. Unfortunately, second- and third-
line drugs for MDR- and XDR-TB are expensive, resulting in the failure of many low-resourced countries 
to afford treatment. This ultimately leads to non-compliance by patients, resulting in high transmission 
of MDR-TB strains in communities.4,8  
 
1.5.5 Challenges associated with current TB chemotherapy 
New anti-TB drugs are required because of the complexity, length, and toxicity of the current TB 
chemotherapy program. As previously mentioned, the incidence of MDR- and XDR-TB continues to 
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increase (Figure 1.9), and the next generation of anti-TB drugs should therefore inhibit new targets. 
Furthermore, there is growing awareness of the need for new anti-TB drugs to cure Mtb in different 
physiological states, including LTBI. It is estimated that one third of the world’s population is infected 















Figure 1.9 Proportion of MDR-TB and XDR-TB incidence in 20183,4  
 
 
Considering that the majority of highly TB-burdened countries are developing countries, there will 
always be a demand for inexpensive and easily accessible drugs. Therefore, new anti-TB drugs need 
to provide short, simpler, and affordable multi-drug regimens for DS-TB, and shorter, more effective, 
less toxic, and less expensive regimens for DR-TB.17,20,23 Additionally, TB remains an opportunistic 
infection in an immunocompromised host. Therefore, patients who are co-infected with HIV or 
diabetes require new anti-TB drugs that cause fewer drug-drug interactions and are compatible with 
antiretroviral drugs (ARVs).11,17,20 For example, RIF cannot be combined with the ARVs indicated in 
Figure 1.10 because of unfavourable drug-drug interactions and additive toxicities. This is because RIF 
is a potent inducer of cytochrome P450 (CYP) enzymes, which are responsible for metabolizing ARVs 
to their inactive metabolites, thereby reducing effective serum concentration and exposure. Thus, co-
infected patients are required to complete TB treatment first before initiating HIV treatment, which 







Figure 1.10: ARV drugs that show drug-drug interactions with RIF 
 
 
1.5.6 Advances in the development of new anti-TB drugs 
After half a century with no new anti-TB drugs developed, a promising pipeline has emerged during 
the last 5 years. The recent increase in TB drug portfolio is driven by the repurposing of old drugs, 
repositioning of existing anti-bacterial compounds, and discovery of new drug leads.17 There are 









Bedaquiline (Figure 1.12), one of the most noteworthy compounds, is a bactericidal drug that belongs 
to the class of diarylquinolines.21 Its mechanism of action (MoA) involves inhibition of mycobacterial 
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ATP synthase, an enzyme essential for energy generation. Although bedaquiline received accelerated 
approval from the United States Food & Drug Administration (FDA) in 2012, its development in clinical 
trials lasted 10–15 years.22-23  
Bedaquiline was discovered through a whole-bacteria screening approach and early mouse studies 
suggested its treatment-shortening potential. This led to its progression to phase II studies, which 
showed that administration of bedaquiline in combination with drugs already used in the treatment 
of XDR-TB significantly reduced the sputum culture conversion time.21-22 Bedaquiline was thus added 
to the existing drug treatment regimen for patients with extrapulmonary TB, pregnant women, HIV/TB 
co-infected patients, and adults with MDR-TB. Unfortunately, safety concerns were raised during 
phase IIb trials because of the unexplained higher mortality rate detected in the group treated with 
bedaquiline compared to that in the placebo group.25-26  
Nitroimidazoles include two prodrugs: delamanid and pretomanid (Figure 1.12). These prodrugs are 
selectively active against both replicating and non-replicating Mtb. They are activated by deazaflavin-
dependent nitroreductase enzyme and their MoA involves inhibition of Mtb cell wall synthesis and 
cell respiration. Delamanid has been approved for use by the FDA to treat MDR-TB in patients for 





Figure 1.12 Chemical structures of new anti-TB drugs in clinical trials and those recently approved22-28 
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Oxazolidinones, such as linezolid and sutezolid, are repurposed agents. The MoA of these drugs is the 
inhibition of mycobacterial protein synthesis but also that of human mitochondria. However, the 
efficacy and toxicity of oxazolidinones are caused by similar mechanisms. Their usability in clinic 
therefore depends on differential effects on the bacteria in contrast to that in the human 
mitochondria.29-30 Fortunately, linezolid has been used for the treatment of highly resistant TB for 
many years. In addition to this, a 2012 clinical trial clearly showed that linezolid activity improved 
when used in combination with other drugs for the treatment of MDR-TB.31 
Other compounds that have been repurposed for the treatment of TB include fluoroquinolones, 
gatifloxacin, and moxifloxacin (Figure 1.12). These were originally developed for treatment of 
respiratory tract infections, and fluoroquinolones have been commonly used as second-line drugs for 
DR-TB as well as in patients who cannot tolerate first-line agents.  
In summary, the past decade has seen some promising advances in the development of anti-TB drugs. 
However, there are some notable gaps in clinical development, as well as an insufficient number of 
drug candidates in the later stages of development. Therefore, there is an ongoing need to develop 
potent drugs that can combat the various limitations of the current regimens. 
 
1.6 D-Cycloserine (DCS) 
DCS (Figure 1.6) is an oral, bacteriostatic, second-line anti-tubercular drug that is primarily used for 
the treatment of MDR-TB.1–3 In addition to this, DCS has been explored as a potential treatment agent 
for various neuropsychiatric conditions as it is a partial agonist of the glycine binding site of the N-
methyl-D-aspartate (NMDA) receptor in the central nervous system (CNS).5 DCS is a cyclic analogue of 
D-alanine, which is an essential amino acid for peptidoglycan synthesis.  
DCS functions by competitively inhibiting two important enzymes in the alanine metabolic pathway: 
alanine racemase (Alr) and D-alanine:D-alanine ligase (Ddl). These two enzymes are essential for the 
biosynthesis of the peptidoglycan cell wall. Alr is key for the conversion of L-alanine to D-alanine, 
which combines with another D-alanine molecule to produce a dipeptide. This dipeptide is formed by 





Figure 1.13: Schematic representation of pathways that synthesize D-alanine 33-35 
D-cycloserine (DCS) inhibits the primary pathway of D-alanine production (red) and inhibits D-alanine:D-alanine 
ligase (Ddl, pink) which ultimately inhibits peptidoglycan biosynthesis of the mycobacterial cell wall. Alr, alanine 
racemase; TCA cycle, tricarboxylic acid cycle. 
 
As seen in Figure 1.13, Mtb encodes enzymes that synthesize branched-chain amino acids, thereby 
making these pathways attractive targets for the development of novel antibiotics. Specifically, the 
pyridoxal 5’-phosphate (PLP)-dependent transaminases perform the final biosynthetic step in the L-
leucine, L-isoleucine, and L-valine pathways by producing chain amino acids from an α-keto acid 
precursor using chain amino acid transaminase. DCS has been shown to irreversibly inhibit bacterial 
D-amino acid transaminase and a recent study also showed that DCS inhibits Mtb’s branched-chain 
amino acid transaminase (MtIlvE).35-36  
DCS is a noteworthy drug because, among its many advantages, it shows high gastric tolerability in 
comparison to other drugs within this group, as well as the absence of cross-resistance to other drugs 
in the treatment of DR-TB. However, just like other second-line anti-TB drugs, DCS displays significant 
toxicity. This ranges from relatively mild side effects such as dizziness, headaches, tremors, slurred 
speech, insomnia, anxiety, lethargy, and inability to concentrate, to more serious side effects including 
severe depression, psychosis, and seizures.20,32,37 Nevertheless, DCS remains a cornerstone drug for 
the treatment of MDR- and XDR-TB, thus making this compound an attractive prototype for the 
development of novel antitubercular drugs. 
Terizidone (Figure 1.14), a derivative of DCS, is a broad-spectrum antibiotic that shows great 
improvement of the disadvantages associated with DCS, such as an improved safety profile.37 
Terizidone acts as a pro-drug, which may be defined as a pharmacologically inactive form of a drug 




Figure 1.14: Hypothetical description of the probable pro-drug-based activity of terizidone29 
 
 
1.7 Research program 
1.7.1 Rationale 
As shown in the literature review, there is an urgent need to develop novel anti-TB agents with 
enhanced potency, novel mechanisms of action, and improved safety and efficacy profiles against 
both DS and DR strains of Mtb. The literature review also highlighted the adequate space to study and 
investigate DCS analogues as potential anti-TB drug leads. 
 
1.7.2 Hypothesis 




The overall objective of this work was to utilize DCS and its synthetic analogue terizidone as starting 
points for antimycobacterial structure-activity relationship (SAR) and structure-property relationship 
(SPR) studies for the target compounds. 
 
1.7.4 Specific aims 
Synthesize different sets of compounds: (i) DCS analogues and (ii) hybrid analogues combining DCS 
with other anti-TB drugs (Chapter 2). 
Biologically evaluate the antimycobacterial potency, cytotoxicity, and in relevant cases microsomal 
stability of target compounds synthesized (Chapter 3). 
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Chapter 2: Design and synthesis of derivatives 
 
2.1 Chapter overview 
In this chapter, the concept of hybrid molecules and prodrugs is briefly outlined and the design, 
synthesis, and spectroscopic characterization of D-cycloserine (DCS) derivatives are presented.  
 
2.2 Introduction 
DCS (Figure 2.1A) is a natural product derived from Streptomyces orchidaceous and Streptomyces 
garyphalus that was first isolated in the 1950s.1–3 DCS is a cyclic analogue of the amino acid D-alanine 
(Figure 2.1B), which is an essential metabolite for peptidoglycan synthesis. DCS is a broad-spectrum 
agent that is active against both gram-positive and -negative bacteria and is primarily used to treat 
MDR-TB.4 DCS interferes with bacterial cell wall synthesis by competitively inhibiting the enzymes L-
alanine racemase and D-alanine:D-alanine ligase (Ddl), thereby inhibiting peptidoglycan formation in 
the cell wall of Mtb.1,2,5  
 
Figure 2.1: Chemical structures of D-cycloserine (A), D-alanine (B), and terizidone (C)1-3,8 
Like other second-line anti-TB drugs, DCS displays significant toxicity. This ranges from relatively mild 
side effects such as dizziness, headaches, tremors, insomnia, and anxiety to severe depression and 
psychosis. Thus, the propensity of DCS to cause profound neuropsychiatric side effects and the limited 
data available showing its efficacy against Mtb mean that it is often used as a last-line treatment 
option. However, despite these drawbacks, the emergence of MDR-TB and extensively drug-resistant 
TB (XDR-TB) has rendered its use in TB treatment necessary.3,7,8 Conversely, terizidone (Figure 2.1C), 
a derivative of DCS, is a broad-spectrum antibiotic with a greatly improved safety profile compared to 
that of DCS.8 Nevertheless, DCS remains a cornerstone drug for the treatment of MDR-TB and XDR-





2.3 Design of DCS derivatives 
2.3.1 Prodrugs 
Prodrugs are inactive, bio-reversible derivatives of drug molecules designed to undergo in vivo 
enzymatic and/or chemical transformation to release the active parent drug, which then exerts the 
desired pharmacological effect at efficacious levels.9-12 Prodrugs represent a widely used strategy for 
enhancing the pharmacokinetic, physicochemical, and biopharmaceutical properties of 
pharmacological agents in drug discovery and development.14-15 The prodrug approach has been 
successfully applied to a wide variety of drugs and it is estimated that 10% of drugs currently marketed 
worldwide can be classified as prodrugs.12 Some of the undesirable properties that have been 
successfully addressed by using a prodrug approach include low bioavailability, formulation 
challenges, and poor drug delivery such as low aqueous solubility, poor oral absorption, rapid 
metabolism, and toxicity.8,12,16-17 
 
2.3.2 Classification of prodrugs  
Generally, prodrugs only require one or two chemical and/or enzymatic biotransformation processes 
to yield the pharmacologically active compound (Figure 2.2).17  
 
Figure 2.2: Illustration of the prodrug concept (adapted from Rautio et al. 2008)17  
Prodrugs are classified according to derivatization and the type of carrier attached to the drug. 
Therefore, prodrugs can be classified into two categories: carrier-linked prodrugs and bioprecursors. 
In carrier-linked prodrugs, the promoiety is covalently linked to the active drug but can easily be 
cleaved enzymatically or non-enzymatically to furnish the parent drug.18 Bioprecursor drugs result 
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from modification of the active drug itself, yielding a novel compound that is subsequently chemically 
or enzymatically converted to the active metabolite.17 An important factor to be considered in prodrug 
design is the presence of functional groups in the molecule that are predisposed to chemical prodrug 
derivatization. Generally, the most commonly used functional groups are hydroxyl, carboxylic acid, 
amine, and phosphonate groups.17 The modification of these groups produces esters, amides, 
carbonates, and phosphate group prodrugs among others.17  
The use of amides as prodrugs is less common, owing to their relatively high enzymatic stability in 
vivo. However, amides are often used to enhance oral absorption and in the synthesis of specific 
intestinal uptake transporter substrates.10,17 Once administrated, the amide bond is hydrolysed by 
ubiquitous carboxylesterases, peptidases, or proteases.19 An example of a clinically used amide 
prodrug is the anti-TB agent pyrazinamide (PZA). PZA undergoes enzymatic hydrolysis as it is a 
substrate of mycobacterial and host amidase, which hydrolyses it to pyrazinoic acid (POA), the 
pharmacologically active moiety.20  
In contrast, esters are the most common prodrugs and are estimated to make up 49% of all marketed 
prodrugs.14 Ester prodrugs are often used to enhance the lipophilicity and thus membrane 
permeability of hydrophilic drugs by masking charged groups such as carboxylic acids and 
phosphates.17,21 Once administered, the ester bond is hydrolysed by ubiquitous carboxylesterases, 
acetylcholinesterases, or arylesterases to the respective alcohol and carboxylic acid. An example of a 
clinically used ester prodrug is the enzyme (ACE) inhibitor enalapril, which exhibits improved 
bioavailability.17 Examples of ester and amide prodrugs are listed in Table 2.1.  
 




Prodrug name Functional 
group 
Structure Pharmacologically active 
metabolite/moiety 














2.3.3 Hybrid drugs 
A hybrid compound is a compound that has been chemically modified by combining two or more 
pharmacophoric units of different known bioactive molecules, either directly or via a linker, to form a 
single chemical entity.22 Hybrid molecules offer several advantages over combination therapy and 
single molecules. Drug hybrids have the potential to reduce the emergence and spread of resistance 
to treatment by combining two pharmacophores that exert dual or multiple drug action into a single 
chemical entity with different modes of action.23-25 These combinations may lead to synergistic effects, 
resulting in an increased potency. Physicochemical properties (e.g., solubility and permeability) can 
be improved by incorporating moieties with the desired properties.23-25 Drug interactions leading to 
synergy may result from a simple uptake effect, as the increased permeability of one drug may cause 
accumulation of the other, thus improving treatment efficacy. This uptake effect has been shown in 
interactions between aminoglycosides and β-lactam antibiotics.26 In addition, it is possible to impart 
selectivity for a drug target such as a receptor. For example, the anti-cancer hybrid drug estramustine 
was designed to selectively deliver toxic mustard to cancer cells by binding to steroid receptors on 
prostate tumours.27 Lastly, hybrid molecules are able to overcome the additive toxic effects of 
individual drugs with the added convenience of a single formulation, thus improving overall patient 
adherence at a potentially lower cost.23,28  
 
2.3.4 Classification of hybrid drugs 
Hybrid molecules may be classified into three distinct groups: (i) cleavable, (ii) non-cleavable, and (iii) 
merged or overlapping hybrids (Figure 2.3). Cleavable hybrids are covalently linked directly or 
indirectly through a spacer devised to be hydrolysed, usually enzymatically. These linkers are generally 
esters, amides, or carbamates. Upon hydrolysis, the two bioactive motifs are expected to elicit their 
pharmacological effects individually.27 Non-cleavable hybrid molecules are covalently linked but differ 
from cleavable hybrids as they are designed to retain their biological activities in their single hybrid 
forms. In contrast, merged or overlapping hybrids are designed by overlapping the common structural 
motifs of two or more pharmacophores and elicit a pharmacological effect that is distinct from that of 




Figure 2.3: Classification of hybirds27 
 
2.4 Design and rationale of DCS derivatives  
The efficacy of a drug is determined by its various physiochemical properties including absorption, 
distribution, mechanism of interaction between the drug and its cellular target, metabolism, 
excretion, and toxicity. Lipophilicity and solubility are two key factors that affect both the extent and 
rate of drug absorption.28 TB treatment is further challenged by the existence of a barrier called the 
caesium, a necrotic and hydrophobic ring that consists chiefly of immune cells such as macrophages 
and neutrophils encasing the bacilli.29-30 This presents the added challenge of drug penetration into 
the necrotic lesions where persistent bacilli reside, requiring a hydrophobic/hydrophilic balance to 
achieve an effective concentration for antimycobacterial activity.29,31  
As discussed, DCS’s main liability is it toxicity. However, its structural analogue terizidone has shown 
improved potency and reduced toxicity. Although the discovery of terizidone was serendipitous, it 
functions and behaves similarly to a prodrug. Therefore, it was hypothesized that introducing a 
lipophilic carrier to DCS may produce a new entity with the same metabolic fate as terizidone. This 
was hypothesized to consequently potentially reduce toxicity while maintaining and/or enhancing the 
potency of DCS. In order to explore this class of compounds, structural changes around DCS were 
proposed. A variety of analogues were selected based on this, resulting in two points of diversity, SAR 








Figure 2.4: Chemistry plan for the synthesis of D-cycloserine analogues 
 
 
Inspired by the structure of terizidone, a prodrug approach was employed to synthesize DCS-mono- and 
di-amide derivatives as well as DCS-imine derivatives. This involved the introduction of one or two units of 
DCS covalently linked by an inert carrier group with the hypothesis that they would be metabolized to DCS 
through in vivo hydrolysis by Mtb enzymes and/or host enzymes.  
Desired chemical and biological properties may be obtained by manipulating the compounds’ 
physicochemical properties using a Craig plot (Figure 2.5). A Craig plot predicts the correlation between 
the physicochemical properties of a drug and its biological activity through a graph of the hydrophobic 
character (π) of a substituent and its electronic effects (Hammett substitution, σ).32 Therefore, to create 
structural diversity, different X, Y, and Z substituents from the four quadrants of the Craig plot were used 




























































Additionally, amide derivatives including the prodrug PZA and the DCS moiety were also designed. 
Similarly, the compound NITD S5 (Figure 2.6) was covalently coupled to the DCS moiety to generate 
amide prodrug-like derivatives. The prodrug PZA (Table 2.1) and NITD S5 (Figure 2.6) were chosen 
because of their high potency against Mtb. As discussed, the active metabolite of PZA is POA, which is 
secreted by a weak efflux pump and is converted to the protonated conjugate acid. This protonated 
conjugate acid may re-enter the cell and accumulate as a result of inefficiency of the efflux pump in 
removing the drug, thus causing non-specific damage to the bacillus.  
 
Figure 2.6: Chemical structure and biological activity of the hit compound NITD S5. 
MIC99: minimum inhibitory concentration causing 99% inhibition. 
 
It is for this reason that hybrid approaches were considered to combine both PZA and NITD S5 with 
DCS, based on the hypothesis that once administered, these would release DCS, POA, and NITD S5 as 
active metabolites in vivo.  
 
2.5 Synthesis and characterization of D-CS derivatives 
2.5.1 Synthesis of SAR 1 target compounds 
The novel (with an exception of compound 1.1) isoxazolidine-3-one-imines were synthesized using the 
procedure described by Ernst Felder et al.,33 with modifications. The target compounds were furnished 
by a Schiff base-type condensation between the commercially available relevant aldehyde and an 
excess of DCS (Scheme 2.1). The reactions were carried out under reflux in methanol, affording the 
desired products (1.1-1.11) in low to high yields (4-88%) without the use of column chromatography 
for purification (Table 2.2). Compounds were characterized via nuclear magnetic resonance (NMR) 
and mass spectrometry, and their melting points determined.  
 
Scheme 2.1: General synthetic protocol of isoxazolidin-3-one-imines 
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Reagents and conditions: methanol, 65 ᵒC, 10 min, 4-88 % 
 









H H 88 
 1.2 H H H 20 
 1.3 CH3 H H 35 
 1.4 CN H H 10 
 1.5 OCH3 H H 59 
 1.6 H OCH3 H 4 
 1.7 H H OCH3 47 
 1.8 H F H 44 
 1.9 F H H 41 
 1.10 H H F 49 
 1.11 Br H H 28 
 
2.5.2 Mechanistic details and spectroscopic analyses of SAR 1 target compounds 
For mechanistic purposes, compound 1.5 will be used as an illustrative example. The formation of 
target compound 1.5 (Figure 2.7) is initiated by nucleophilic attack of DCS’s amino nitrogen onto the 
electron-deficient carbonyl carbon of p-anisaldehyde. This is followed by a proton transfer step 
between the amine and the negatively charged oxygen. Subsequently, abstraction of an acidic 
methanolic proton occurs, resulting in the protonation of the hydroxyl group, thus making it a stronger 
leaving group. Intramolecular elimination of a water molecule results in the formation of an iminium 
ion intermediate. Lastly, a deprotonation step of the iminium yields final targets 1.1-1.11 maintaining 




Figure 2.7: Proposed reaction mechanism for the formation of final target 1.5 
 AN: nucleophilic addition, P.T: proton transfer, E: elimination 
 
NMR assignments for final target compounds (1.1-1.11) were assisted by both one-dimensional (1D) 
proton and carbon (1H and 13C) as well as two-dimensional (2D) heteronuclear single quantum 
correlation (HSQC) and correlation spectroscopy (COSY) NMR experiments. For characterization 
purposes, compounds 1.5-1.10 will be used as illustrative examples to highlight the NMR spectral 
differences between ortho-, meta-, and para-substituted analogues. All p-isoxazolidine Schiff base 
analogues (1.3, 1.4, 1.9, and 1.11) exhibited similar 1H-NMR spectra as that of 1.5 (Figure 2.8). 
The successful incorporation of DCS into the molecule was confirmed by the appearance of distinctive 
multiplicity signals in the aliphatic region. A multiplet at δH = 4.32 ppm integrating for two protons 
(2H), was attributed to protons H2a and H2b, while another multiplet at δH = 4.14 ppm integrating for 
one proton (1H), was assigned to H3. The signals of the phenyl ring hydrogens were observed in the 
aromatic region of the 1H-NMR spectrum resonating as a pair of doublets at δH = 7.54 and 6.96 ppm 
with similar coupling constants of J = 8.85 and 8.78 Hz, respectively. These were unambiguously 
assigned to protons H5 and H6, respectively. Meanwhile, the olefinic proton H4 of the imine was 
observed as a singlet at δH = 8.18 ppm. Furthermore, the NH proton of the D-CS moiety resonated as 
a singlet at the most downfield chemical shift (δH = 8.31 ppm). The methoxy protons (H7) appeared at 




Figure 2.8: Assigned 1H-NMR spectrum confirming the successful synthesis of target compound 1.5 
 
The 1H-NMR spectra acquired for the ortho-substituted isoxazolidine Schiff base analogues (1.7 and 
1.10) are exemplified by the 1H-NMR spectrum of compound 1.7 (Figure 2.9). Each aromatic proton 
of the phenyl ring exhibited a unique chemical shift, and this was attributed to the fact that the 
methoxy group was in the ortho position. The distinctive multiplicity pattern in the aromatic region 
includes a doublet of doublet of doublets (ddd) at δH = 7.40 ppm, which was assigned to proton H7. 
This proton experiences a close range (J3) coupling to protons H6 and H8, as confirmed by the large 
coupling constants (J = 8.79 and 7.52 Hz, respectively), and long-range coupling to proton H5, as 
confirmed by the small coupling constant (J = 1.81 Hz). Proton H5 splits as a doublet of doublets at δH 
= 7.63 ppm. This proton experiences long-range coupling to proton H7, as seen by the small coupling 
constant observed (J = 1.72 Hz). In addition, H5 also experiences vicinal coupling to proton H6, as 
confirmed by the comparatively large coupling constant (J = 7.66 Hz). Proton H8 resonates as a doublet 
at δH = 7.06 ppm and shows short-range coupling with H7, as confirmed by the large coupling constant 
J = 8.35 Hz. In addition to this, what appears to be a triplet at δH = 6.95 ppm is in fact a coalesced 
doublet of doublets corresponding to proton H6. This proton experiences vicinal (J3) coupling to 
protons H7 and H5, as confirmed by the large coupling constants (J = 8.78 and 7.66 Hz). Finally, the 
46 
 
proton signals of DCS and the methyl group of the methoxy were not significantly influenced by the 
change in position of the methoxy group on the phenyl ring, and their chemical shift values are 
therefore very similar to those of 1.5 (Figure 2.8). 
 
Figure 2.9: Assigned 1H-NMR spectrum confirming the successful synthesis of target compound 1.7 
 
The 1H-NMR spectra acquired for the meta-substituted isoxazolidine Schiff base analogues (1.6 and 
1.8) are exemplified by the 1H-NMR spectrum of compound 1.6 (Figure 2.10). The distinctive 
multiplicity patterns observed in the aromatic region include a ddd at δH = 6.98 ppm, which was 
unambiguously attributed to proton H8. This proton experiences long-range (J4) coupling with protons 
H6 and H5, as confirmed by the small coupling constants of J = 2.60 and 1.07 Hz, respectively, and 
close-range vicinal coupling to H7 with a correspondingly larger coupling constant of J = 8.26 Hz. In 
addition to this, the two unusual multiplets at δH = 7.32 and 7.16 ppm correspond to protons H7 and 
H5,6. Finally, the proton signals of DCS and the methyl group of the methoxy were not significantly 
influenced by the change in position of the methoxy group on the phenyl ring, and their chemical shifts 




Figure 2.10: Assigned 1H-NMR spectrum confirming the successful synthesis of target compound 1.6 
 
2.5.3 Synthesis of SAR 2 target compounds 
The 3-isoxazolidin-4-yl amides were synthesized according to Scheme 2.2. The commercially available 
relevant carboxylic acid underwent chlorination by heating under reflux in thionyl chloride (SOCl2) or 
at room temperature (20-24 ᵒC) in oxalyl chloride to yield the relevant acyl chloride intermediates. DCS 
was then coupled to these acyl chloride intermediates to yield the desired products 3.1-3.5 in very 
low to low yields (5-21%; Table 2.3). 
Scheme 2.2: Synthetic protocol for target compounds 3.1-3.5 
Reagents and conditions: (i) SOCl2, toluene (3.4), neat (3.2, 3.3), reflux (75 ᵒC), 12-15 h/oxalyl chloride, 
dichloromethane (DCM), catalytic dimethylformamide (DMF) (3.1, 3.5), 20-24 ᵒC; (ii) D-CS, triethylamine (TEA), 
DMF/N-methyl-2-pyrrolidone (NMP), RT (20-24 ᵒC), 3-4 h 
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X Y Z % Yield 
3.1 H CH CH 19 
3.2 OCH3 CH CH 20 
3.3 Br CH CH 5 
3.4 H N CH 21 
3.5 
 
CH CH 3 
 
 
The reaction for step (i) is initiated by nucleophilic attack of the hydroxyl oxygen of the carboxylic acid 
on the electron-deficient thionyl chloride sulphur (Figure 2.11), resulting in the formation of an 
unstable tetrahedral intermediate. The intermediate collapses as the chloride ion is expelled, thus 
deprotonating the resulting intermediate to form a chlorosulfide anhydride and hydrochloric acid as 
a by-product. In the final step, the chlorosulfide intermediate undergoes nucleophilic substitution as 
the chloride attacks the carbonyl carbon, subsequently resulting in the formation of the carbonyl 
chloride with sulphur dioxide and hydrogen chloride gas as by-products.  
 
Figure 2.11: Proposed reaction mechanism for the formation of the acyl chloride intermediate 
 
All acyl chloride intermediates (2.1-2.5) were used without purification or characterization. The next 
step was the introduction of D-CS into the molecule via nucleophilic substitution of the chloro group 




The appearance of new proton signals corresponding to DCS in the 1H-NMR spectrum (Figure 2.13) 
confirmed that a successful nucleophilic substitution reaction had occurred. These characteristic 
signals include the broad NH singlet at δH = 11.51 ppm and the amide doublet at δH = 8.93 ppm. These 
were assigned to H1 and H4, respectively. In addition to this, distinctive multiplicity patterns in the 
aliphatic region, including a doublet of doublets at δH = 4.12 ppm, were observed and attributed to 
proton H2a. This proton experiences vicinal coupling with proton H3, as confirmed by the relatively 
small coupling constant (J = 8.32 Hz), and germinal coupling with H2b, as indicated by the large 
coupling constant (J = 10.38 Hz). The unusual quartet at δH = 5.05 ppm was attributed to proton H3. A 
pair of doublet of doublets at δH = 7.88 and 7.49 ppm were unambiguously assigned to protons H5 

















Figure 2.12: 1H-NMR spectrum of compound 3.1 
 
The successful incorporation of two units of D-CS into the molecule was confirmed by the distinctive 
multiplicity pattern in the aliphatic region (Figure 2.14). A two-proton doublet of doublets signal at δH 
= 4.12 ppm was attributed to protons H2a and a triplet at δH = 4.58 ppm corresponding to two protons 
was assigned to H2b, as confirmed by the coupling constants. The quartet observed at δH = 5.05 ppm 
was attributed to proton H3, accounting for two protons. The aromatic signals of the phenyl ring were 
observed at δH = 7.97 ppm corresponding to four H5 protons. Furthermore, the NH protons of the 
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amide resonated as a doublet at δH = 9.08 ppm while the NH protons of the DCS ring resonated as a 
broad singlet at the most downfield chemical shift (δH = 11.51 ppm). Furthermore, data obtained from 
LC-MS provided more information on the structural characteristics of compound 2.14. The LC 
chromatogram provided the purity as > 99%, based on the percentage peak area; the mass spectrum 
exhibited a pseudo-molecular ion [(M+H)+] of 334.09 as the base peak (100%), corresponding to the 





Figure 2.14: 1H-NMR spectrum of compound 3.5 
 
The successful incorporation of DCS into the pyrazine motif was confirmed by distinctive multiplicity 
in the aliphatic region (see spectrum for compound 3.4 in Figure 2.15 and Figure 2.16). These 
characteristic signals include the broad NH singlet at δH = 11.55 ppm and the amide doublet at δH = 
9.32 ppm. These were assigned to H1 and H4, respectively. In addition to this, another distinctive 
multiplicity pattern including a doublet of doublets at δH = 4.25 ppm was observed and attributed to 
proton H2a. This proton experiences vicinal coupling with proton H3, as confirmed by the coupling 
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constant (J = 8.17 Hz), and germinal coupling with H2b, as indicated by the larger coupling constant (J 
= 11.06 Hz). The doublet of triplets at δH = 5.06 ppm was attributed to proton H3, which experiences 
unequal coupling to protons H2 and H4. 
Lastly, pyrazinyl hydrogens were accurately assigned using 2D COSY and HSQC (Figure 2.16). The 
doublets at δH = 9.20 and 8.90 ppm were unambiguously assigned to protons H5 and H6, respectively. 
H5 resonates as a simple doublet as the small coupling constant (J = 1.46 Hz) corresponding to proton 
H5 suggests that this proton experiences only long-range coupling to H6. The doublet of doublets 
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Chapter 3: Pharmacological evaluation 
 
3.1 Chapter overview 
This chapter describes the biological studies that were conducted to evaluate the antimycobacterial 
potency, cytotoxicity, and (in one case) microsomal stability of the synthesized target molecules. 











Figure 3.1: Screening cascade used for the biological evaluation of target compounds  
CHO, Chinese hamster ovarian cells; HepG2, Human hepatic cells; MIC90, 90% minimum inhibitory concentration; 
HLM, human liver microsomes; RLM, rat liver microsomes; MLM, mouse liver microsomes; DCS, D-cycloserine 
 
Compounds were submitted for evaluation of antimycobacterial activity against M. smegmatis 
(Mc2 155, M. smeg) and M. tuberculosis H37Rv strains, cytotoxicity in Chinese hamster ovarian (CHO) 
and human hepatic (HepG2) cells, and solubility studies using turbidimetric and HPLC-based kinetic 
solubility assays. The microsomal metabolic stability of any compound with minimum inhibitory 
concentration (MIC90) ≤10 µM was assessed in human liver microsomes (HLM), rat liver microsomes 
(RLM), and mouse liver microsomes (MLM). 
In metabolic stability assays, any analogue for which >75% of the parent compound remained present 
after 30 min incubation was deemed metabolically stable. Any compound that fulfilled these criteria 
would under normally be subjected to further in vivo tests to investigate pharmacokinetic (PK) 
properties such as bioavailability, exposure, and clearance for efficacy studies in a mouse model. 
However, these assays were not carried out here as this was beyond the scope of the project. 
 
>75 % remaining after 30 mins 
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3.2 Evaluation of in vitro antimycobacterial activity against M. smegmatis and M. 
tuberculosis 
3.2.1 In vitro antimycobacterial activity 
The in vitro antimycobacterial activities of all compounds were evaluated against M. smegmatis 
(Mc2 155, M. smeg) and M. tuberculosis H37Rv under replicating conditions. All assays were conducted 
according to laboratory standard operating procedures (SOPs). Assays evaluating activity against M. 
smeg were performed in Luria Broth (LB) medium using RIF as the reference drug. Assays evaluating 
activity against the H37Rv strain of Mtb were conducted by the TB Biology group at the Drug Discovery 
and Development Centre (H3D), based at the Institute of Infectious Diseases and Molecular Medicine 
(IDM), University of Cape Town, South Africa. These assays were performed in three different types 
of growth media; Middlebrook 7H9 GLU ADC TW (7H9 medium enriched with albumin-dextrose-
catalase (ADC) and supplemented with 0.4% glucose and 0.05% Tween 80), Middlebrook 7H9 ADC TW 
(7H9 medium enriched with ADC and supplemented with 0.05% Tween 80), and Middlebrook 7H9 GLU 
ADC (7H9 medium enriched with ADC and supplemented with 0.4% glucose). 
M. smeg has been used extensively as a non-pathogenic surrogate to study highly pathogenic Mtb 
physiology because of its ease of manipulation in a biosafety level 1 facility, close resemblance to Mtb 
with regard to both structural and genetic features, and its significantly shorter doubling time in 
comparison to that of Mtb.1 In addition to studying mycobacterial physiology, numerous reports in 
the literature have indicated its usefulness in antimycobacterial compound screens. For instance, 
bedaquiline, the first novel anti-tuberculous agent to be approved for clinical use after over four 
decades, was initially discovered after a screening campaign in M. smeg. 2 However, considering the 
phenotypic and genotypic differences between M. smeg and Mtb, there are limitations to the 
applicability of results obtained in M. smeg in drug discovery. 
Test compounds were stratified into four categories for the purpose of this SAR analysis. All 
compounds with MIC90 ≤ 10 µM were regarded as active, those with MIC90 10 to 20 µM as moderately 
active, MIC90 values between 20 and 125 µM denoted as having poor activity, and compounds with 
MIC90 > 125 µM were categorized as inactive. As shown in Tables 3.1 and 3.2, compounds showed 
little or no glycerol-dependent activity and no differences in activity against Mtb were observed in 
media with and without Tween-80. Furthermore, structural changes in SAR 1 and SAR 2 generally 
yielded inactive compounds. For instance, all isoxazolidine-3-one imines analogues were inactive, with 
the exception of compound 1.1, which displayed high activity (7.81 µM). Similarly, in SAR 2, all 3-
isoxazolidin-4-yl amide analogues were inactive with the exception of 3.3 (2.90 µM), which was active 
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across all three media types. Notably, the replacement of bromo (3.3) with methoxy (3.2) or a proton 
(3.1) abolished activity. 
Overall, antimycobacterial activity appeared generally to be independent of electronic properties and 
hydrophobicity imparted by various substituents
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Table 3.1: In vitro antimycobacterial activities of SAR 1 target compounds against Mycobacterium smegmatis and Mycobacterium tuberculosis (Mtb) 
 
 




X Y Z 
     
 







7H9/ADC with Tween 
80 and glycerol 




H H >1654.04 
7.8 7.8 7.8 
 1.2 H H H 1854.20 >125 >125 >125 
 1.3 CH3 H H 1224.11 >125 >125 >125 
 1.4 CN H H 1161.65 >125 >125 >125 
 1.5 OCH3 H H 2270.35 >125 >125 >125 
 1.6 H OCH3 H 1135.17 >125 >125 >125 
 1.7 H H OCH3 >2270.35 >125 >125 >125 
 1.8 H F H >2401.65 >125 >125 >125 
 1.9 F H H >2401.65 >125 >125 >125 
 1.10 H H F >2401.65 >125 >125 >125 
 1.11 Br H H >1858.05 >125 >125 >125 
 Controls  D-Cycloserine  607.38 15.63-31.25 15.63 -31.25 15.63-31.25 
   Rifampicin  97.21 N/A N/A N/A 
MIC90, 90% minimum inhibitory concentration; H37Rv, drug-susceptible Mtb strain; LB, Luria broth; ADC, albumin-dextrose-catalase 
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Table 3.2: In vitro antimycobacterial activities of SAR 2 target compounds against Mycobacterium smegmatis and Mycobacterium tuberculosis (Mtb) 
 
 




X Y Z 
     
 





7H9/ADC with  
glycerol 
7H9/ADC with 





 3.1 H CH CH >2424.830 
>125 >125 >125 
 3.2 OCH3 CH CH >2116.58 >125 >125 >125 
 3.3 Br CH CH >2580.62 2.9 2.9 2.9 
 3.4 H N CH >2401.76 > 125 >125 >125 
 3.5 
 







 3.6 NH2 N CH ND ND ND ND 
 Controls  D-Cycloserine  607.38 15.63-31.25 15.63 -31.25 15.63-31.25 
   Rifampicin  97.21 N/A N/A N/A 
                  MIC90, 90% minimum inhibitory concentration; H37Rv, drug-susceptible Mtb strain; LB, Luria broth; ADC, albumin-dextrose-catalase
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From the data in Tables 3.1 and 3.2 above, a general trend was observed with relatively higher MIC90 
values in M. smeg than in Mtb. To promote visualization, MIC90 values were converted to pMIC90 
(Figure 3.2). The discrepancies observed may be attributed to the genotypic, physiological, and 
metabolic differences between M. smeg and Mtb. Moreover, despite being analogues of DCS, target 
compounds are novel compounds that may have distinct or additional molecular targets besides the 
known target of DCS, and this may result in a different phenotypic profile to that of DCS. 
 
 
Figure 3.2: Graphical representation of MIC90 values in Mycobacterium smegmatis (grey) and in Mycobacterium 
tuberculosis (blue) 




3.2.2 In vitro antibacterial activity against selected gram-positive and -negative pathogens  
There is an urgent need for novel chemotherapeutic agents to control the growing crisis of 
antimicrobial resistance, especially since the end of the “Golden era” of antibiotics, which led to a 
decrease in the discovery of antimicrobials. The target compounds were screened against the top 
priority pathogens responsible for the worldwide spread of antimicrobial resistance identified by the 
WHO.3 These include Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, and 
Enterobacteria species (ESKAPE pathogens). In this experiment, we screened the 16 compounds 
synthesized in SAR 1 and 2 against these pathogens. None of the compounds showed activity 
comparable to that of D-cycloserine, thus confirming selectivity for Mtb (Tables 3.3 and 3.4).   
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 Table 3.3: In vitro anti-bacterial activity of SAR 1 target compounds against ESKAPE pathogens  
 
     MIC90 (µM) 
 Compound 
code 











ATCC 25922  
 1.1 
 
H H 1654.04 >1654.04 827.02 413.51 
 1.2 H H H >2851.42 >2851.42 >2851.42 >2851.42 
 1.3 CH3 H H >2448.22 >2448.22 >2448.22 >2448.22 
 1.4 CN H H >2323.31 2323.31 >2323.31 >2323.31 
 1.5 OCH3 H H >2270.35 >2270.35 >2270.35 >2270.35 
 1.6 H OCH3 H >2270.35 >2270.35 2270.35 >2270.35 
 1.7 H H OCH3 >2270.35 >2270.35 >2270.35 >2270.35 
 1.8 H F H >2401.65 >2401.65 >2401.65 >2401.65 
 1.9 F H H >2401.65 >2401.65 >2401.65 >2401.65 
 1.10 H H F >2401.65 >2401.65 >2401.65 >2401.65 
 1.11 Br H H >1858.05 >1858.05 >1858.05 >1858.05 
 
Controls 
D-cycloserine 607.38 607.38 1214.77 303.69 
 Gentamycin 1.308 0.00374 0.130 0.654 
 Streptomycin 4.298 0.00749 1.719 8.597 
 MIC90, 90% minimum inhibitory concentration 
 Studies were performed in Muller-Hinton Broth and reported as MIC90 values at day 8.  
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Table 3.4: In vitro anti-bacterial activity of SAR 2 target compounds against ESKAPE pathogens  
 
 
        MIC90 (µM) 












3.1 H CH CH >2424.830 >2424.830 2424.830 >2424.830 
3.2 OCH3 CH CH >2116.58 2116.58 >2116.58 2116.58 
3.3 Br CH CH >1753.77 >1753.77 >1753.77 >1753.77 
3.4 H N CH 2401.76 >2401.76 2401.76 >2401.76 
3.5 
 
CH CH 1654.04 >1654.04 827.02 413.51 
Controls 
D-Cycloserine 607.38 607.38 1214.77 303.69 
Gentamycin 1.308 0.00374 0.130 0.654 
Streptomycin 4.298 0.00749 1.719 8.597 
Studies were performed in Muller-Hinton Broth and reported as MIC90 values at day 8. 
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3.3 Cytotoxicity  
To determine the safety profiles of the compounds and their selectivity versus Mtb, in vitro 
cytotoxicity studies were performed in two mammalian cells line (CHO and HepG2 cells) at the Division 
of Clinical Pharmacology, University of Cape Town. Cytotoxicity was measured using the well-
established 3-(4,5-dimethylthiazil-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, a colorimetric 
assay that measures cell viability as a function of metabolism/reduction of MTT (yellow colour) to 
formazan (purple colour) by cytosolic NAD(P)H-dependent oxidoreductase enzymes. Emetine was 
used as the positive control and DMSO as the negative control. Cytotoxicity results from these two 
assays (Tables 3.5 and 3.6) were expressed as the concentrations required to inhibit growth by 50% 
(IC50), which were obtained by analyzing dose-response curves. In contrast, in vitro antimycobacterial 
activities were expressed as MIC90, and it would therefore be inaccurate to calculate selectivity indices 
based on these two inhibitory concentrations. The acceptable level of cytotoxicity was thus set as a 
cut-off value of IC50 > 25µM and all compounds exhibited low cytotoxicity (IC50 > 25 µM) against the 
two cell lines. At this juncture, only active compounds 1.1 and 3.3 were advanced to downstream 
biological studies in the screening cascade. 
Table 3.5: In vitro cytotoxicity assay results for SAR 1 target compounds 
 
 
     IC50 (µM) 
 Compound code X Y Z CHO HepG2  
 1.1 
 
H H >50 >50 
 1.2 H H H >50 >50 
 1.3 CH3 H H >50 >50 
 1.4 CN H H >50 >50 
 1.5 OCH3 H H >50 >50 
 1.6 H OCH3 H >50 >50 
 1.7 H H OCH3 >50 >50 
 1.8 H F H >50 >50 
 1.9 F H H >50 >50 
 1.10 H H F >50 >50 
 1.11 Br H H >50 >50 
 Controls  Emetine  0.0139 0.023 




Table 3.6: In vitro cytotoxicity assay results for SAR 2 target compounds 
IC50, 50% inhibitory concentration; CHO, Chinese hamster ovarian cells; HepG2, human hepatic cell line. 
 
3.4 Microsomal stability 
Drug metabolism has implications for drug efficacy and safety as a consequence of one or more of the 
following: (1) enzymatic inactivation (detoxification), (2) biotransformation into active metabolites, 
and (3) enzymatic modification into reactive metabolites that cause toxicity.4-5 Generally, hepatic 
metabolism involves a variety of chemical modifications carried out by an array of enzymes. In 
addition, hepatic metabolism is the primary route of elimination for most xenobiotics, which in turn 
influences their bioavailability, clearance, and half-life. Furthermore, although the liver is the main 
organ at play in drug metabolism, the skin, lungs, blood cells, and plasma also contribute to the 
biotransformation of certain drugs.4-6 
The most commonly used in vitro models are hepatic, as the liver plays a central role as the major 
drug-metabolizing organ. Some of these systems, in decreasing order of biological complexity, include 
whole perfused liver, liver slice, hepatocytes, S9 fractions, and microsomes. Microsomes are the most 
commonly used model as the majority of systems comprise cytochrome P (CYP)450 enzymes, and are 
thus applicable to the metabolism of clinically used drugs. In contrast to the S9 sub-cellular liver 
fractions that most complete sub-cellular fraction at enzymatic liver as the system mostly comprises 
phase I and II enzymes. 
 
 
     IC50 (µM) 
 Compound code 
code 
X Y Z CHO HepG2  
 
 3.1 H CH CH >50 >50 
 3.2 OCH3 CH CH >50 >50 
 3.3 Br CH CH >50 >50 
 3.4 H N CH >50 >50 
 3.5 
 
CH CH >50 >50 
 3.6 NH2 N CH >50 >50 
 Controls  Emetine  0.0139 0.023 
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Therefore, it is important to screen compounds in in vitro assays that employ liver microsomes. Three 
types of liver microsomes (HLMs, RLMs, and MLMs), composed of several membrane-bound enzymes 
such as CYP450 (phase 1 metabolism), are employed to determine any interspecies differences.3 
Rodent models are the most relevant as these are typical animal models for in vivo PK and efficacy 
studies. 
The most potent (MIC90 ≤ 10 µM) and least cytotoxic (IC50 > 25 µM) analogues were selected and their 
in vitro metabolic stability was evaluated. These experiments were conducted by Dr. Mathew Njoroge 
at the Division of Clinical Pharmacology, University of Cape Town. The in vitro metabolic stability of 
compound 3.3 was determined in HLMs, RLMs, and MLMs. Samples were incubated for 30 min and 
analyzed via high-performance liquid chromatography-mass spectrometry (HPLC-MS/MS) to 
determine the percentage remaining. 
 
Table 3.7: Microsomal metabolic stability results of selected compounds, reported as a percentage 
remaining 
HLM, human liver microsomes; RLM; rat liver microsomes; MLM; mice liver microsomes 
 
A percentage remining >75% after 30 min was considered to be within acceptable limits according to 
the screening cascade in Figure 3.1. Therefore, results obtained in Table 3.7 suggest high metabolic 
stability for compound 3.3 in the liver microsomes of all three species. Based on these results, 
compound 3.3 could in future be evaluated further in in vivo PK and efficacy studies in a mouse model 
of tuberculosis as it is expected to show high exposure because of its high metabolic stability in MLMs. 
 
3.5 Conclusion 
In this chapter, various assays were used as part of the biological evaluation of the final target 
compounds synthesized in SAR 1 and 2. The antimycobacterial activities of all compounds synthesized 
were evaluated against Mtb. All compounds were inactive with the exception of compounds 3.3 and 
1.1, which exhibited MIC90 values of 2.9 and 7.8 µM, respectively. None of the 16 compounds whose 
  Metabolic stability (% remaining) 
Compound 
Code 












in vitro antibacterial activities were evaluated against ESKAPE pathogens showed any activity, 
suggesting that these compounds are selective for Mtb in contrast to M. smeg or ESKAPE pathogens. 
All compounds displayed a favourable cytotoxicity profile in both CHO and HepG2 cell lines. Finally, 
the microsomal metabolic stability of the most potent antimycobacterial compound (MIC90 ≤ 10 µM) 
with low cytotoxicity (IC50 > 25 µM) was evaluated. Compound 3.3 displayed high metabolic stability 
in human, mouse, and rat liver microsomes. The aqueous solubility of all compounds synthesized was 
evaluated, and this was analyzed in correlation with selected physicochemical factors in an attempt 
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Chapter 4: Physicochemical profiling 
 
4.1 Chapter overview 
In this chapter, a discussion of the physicochemical properties (solubility, cLogP, melting point, total 
polar surface area, and the presence of hydrogen bond donors and acceptors) of the compounds 
synthesized is provided. Within the context of structure-property relationship (SPR) studies. The 
chapter begins with an outline and discussion of the correlation between the in silico predicted and 
experimentally determined physicochemical properties of the final synthesized target compounds. 
Statistical analyses were performed to establish the disruption profiles of each property across 
compound datasets. Additionally, various compound datasets were statistically evaluated and 
compared, including conventional anti-TB drugs and other drug candidates in clinical development in 
an attempt to establish the chemical space occupied by each cluster of compounds prepared in this 
study. Subsequently, the correlation between measured and predicted parameters was reviewed to 
elucidate the various factors that may contribute to and explain the aqueous solubility observed. 
 
4.2 General introduction 
Physiochemical properties play an integral role in the drug design process as they relate to the in vitro 
potency and in vivo efficacy exhibited by compounds. The impact of physicochemical properties on 
drug action was first rationalized by the early work of Hansch.1–4 However, a more holistic approach 
to the drug design process considers absorption, distribution, metabolism and excretion (ADME) 
characteristics and safety profiles in parallel with target affinity. Ideally, drug candidates should 
possess favourable physicochemical and molecular properties that will increase their chances of 
eventually reaching the market.5 Literature has extensively shown that unfavourable ADME profiles 
and formulation challenges are often attributed to poor physicochemical properties, particularly 
aqueous solubility.6 
Several studies have shown a relationship between physicochemical properties and drug-likeness.6-7 
This led to the determination of a set of guidelines for acceptable cut-off values for calculated 
surrogate molecule descriptors, which are key in predicting optimal physicochemical properties for an 
oral drug-like space. For example, Lipinski’s rule of five (RO5) predicts that a compound is more likely 
to display high oral absorption and permeation when cLogP (the calculated 1-octanol/water partition 
coefficient) is <5, molecular weight (MW) ≤500 Da, number of hydrogen-bond donors (HBD) ≤5, and 
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the number of hydrogen-bond acceptors (HBA) ≤10.7,8 Furthermore, additional guidelines were 
suggested by Veber et al., postulating that compounds with ≤10 rotatable bonds (measure of 
molecular flexibility) and topological polar surface area (tPSA) ≤140 Å2 (or HBD + HBA ≤12) have a 
greater chance of achieving high oral bioavailability.9 
 
4.3 Evaluation of physicochemical properties 
The oral bioavailability of a drug is influenced by its aqueous solubility, permeability, and metabolic 
stability.9 Of these three factors, this study focused mainly on strategies to improve aqueous solubility. 
The molecular descriptors (MW, cLogP, tPSA, HBD, and HBA) relating to the isoxazolidin-3-one-imines 
(ISI) and 3-isoxazolidin-4-yl amides (ISA) synthesized were predicted using StarDrop©6.4 Software to 
establish whether these compounds fall within the chemical space prescribed by the Lipinski’s RO5 
and parameters outlined by Veber et al., which would potentially translate to high oral bioavailability 
during hit-to-led optimization. 
Moreover, because selected compounds displayed antimycobacterial activity, their predicted 
physicochemical properties were compared to those of conventional anti-TB drugs and drug 
candidates currently in clinical development, as mentioned in chapter 1. This was done to establish 
the significance of any similarities or differences between the pairs, which would in turn partially 
explain the activity observed as well as inform the design of analogues with drug-like properties similar 
to those of anti-TB drugs. 
Therefore, for each compound, a Simplified Molecular-Input Line-Entry System (SMILES) was 
generated using ChemBioDraw Ultra and used as the primary format of data entry into StarDrop©6.4 
for property predication. All statistical analyses were performed using Microsoft® office Excel 2018. 
 
4.3.1 Kinetic solubility 
The apparent solubility of all compounds synthesized was determined using a turbidimetric kinetic 
solubility assay. Hydrocortisone and reserpine were used as the respective positive and negative 
controls. The turbidimetric solubility of the target molecules was assessed in 96-well microtiter plates. 
Target molecules were dissolved in dimethyl sulfoxide (DMSO) to obtain 10-mM stock solutions from 
which serial dilutions were prepared in a pre-dilution plate with DMSO to obtain final concentrations 
of 0–10 µM in triplicate. Secondary dilutions were prepared in both DMSO and phosphate-buffered 
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saline (PBS, pH 7.4) to achieve final concentrations of 0–200 µM and incubated at room temperature 
(24–25 ᵒC) for 2 h. 
As their concentration in PBS increases, compounds are expected to precipitate and thus increase 
turbidity, as most organic compounds are not freely soluble in aqueous media. Turbidity was detected 
by measuring the absorbance at 620 nm and the approximate solubility was determined by plotting 
concentration against absorbance. The limit of solubility was determined as the concentration at 
which absorbance of the PBS solution rises above that of the DMSO solution for each compound 
(Chapter 6, Figures 6.3 and 6.4).8,10 
The general classification of turbidimetric solubility for organic compounds using the turbidimetric 
solubility assay is as follows:10 
High: >100 µM 
Moderate: 20–100 µM 
Low: <20 µM 
However, determination of solubility via the turbidimetric method is far less accurate than that using 
high performance liquid chromatography (HPLC). This can be attributed to the non-specificity of the 
assay as the observed values depend on turbidity and solubility may only be determined as part of the 
ranges listed above rather than specific values. Nevertheless, the turbidimetric method is simple as 
well as cost- and time-effective when handling large sample sizes. 
The recorded kinetic solubility values were statistically correlated with experimental factors such as 
melting point, HPLC retention time, and thin liquid chromatography (TLC) retardation factor (Rf). Each 
of these factors was used to measure a particular inherent compound characteristic that subsequently 
influences solubility. For instance, the melting point was used a measure of crystal packing energy, Rt, 
Rf, and tPSA as measures of polarity, and cLogP was indicative of lipophilicity.  
 
4.3.2 HPLC-based solubility 
Additionally, an alternative and more accurate method, which incorporates elements of kinetic and 
thermodynamic solubility in a hybrid method, was used to determine aqueous solubility. In this DMSO 
dry-down method adapted from Zhou et al.,11 high and medium calibration standards (220 and 100 
μM, respectively) in duplicate, as well as samples (200 μM) in triplicate, were added to a 96-well plate 
from a 10-mM stock solution in DMSO. DMSO was then evaporated from the samples for 2 h. 
Standards were dissolved in DMSO again and after vortexing the plate, the high standard was used to 
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prepare a low (11 μM) calibration standard in DMSO. PBS (pH 7.4) was added to the sample wells and 
the plate was incubated for 32 h at 25 °C with shaking. The plate was then centrifuged at 2500 × g for 
30 min and the supernatants were transferred to another plate for analysis. Aqueous solubility was 
calculated using the ratio of the samples’ UV peak areas to that of the standards with best-fit 
calibration curves.12  
The general classification of solubility ranges obtained using the HPLC-based solubility method is 
defined as follows: 
High: >150 µM 
Moderate: 50–150 µM 
Low: 11–50 µM 
Very low: <11 µM 
 
4.3.3 Results and discussion 
The calculated and experimentally determined physicochemical properties of the 3-isoxazolidin-4-yl 









Table 4.1: Physicochemical properties of SAR 2 3-Isoxazolidin-4-yl amides (IZAs) 
 
Abbreviations: MW = molecular weight; cLogP = calculated logarithm of n-octanol/water partition co-efficient; tPSA = topological polar surface area; HBD = hydrogen bond 
donor; HBA = hydrogen bond acceptors; Rf = retardation factor (thin layer chromatography, TLC), tR= retention time (high-performance liquid chromatography, HPLC); m.p = 
melting point. ⱡcalculated using StarDrop©6; aanalytical (TLC) with 80% ethyl acetate in hexane, except 3.5 and 3.6: 5% methanol in dichloromethane; bHPLC-based method 




Calculated physicochemical propertiesⱡ 
 
Experimental physicochemical properties 
Sample 
code 
X Y Z MW (g/mol) cLogP tPSA (Aᵒ2) HBD HBA Rfa tRb (min) m.pc (ᵒC) Turbidime
tric 
Solubility 
at pH 7.4 
(µM) 
3.1 H CH CH 206.20 0.0552 67.43 2 5 0.13 0.45 187.3-186.6 200 
3.2 OCH3 CH CH 236.23 0.0460 76.66 2 6 0.12 0.57 315.2-317.8 160 
3.3 Br CH CH 269.10 0.8116 67.43 2 5 0.14 0.75 317.4-318.8 200 
3.4 H N N 208.18 -0.5127 93.21 2 7 0.11 0.17 313.5-318.2 200 
3.5 
 
CH CH 334.29 -0.3416 134.90 4 10 0.08 0.29 366.1-368.2 200 
3.6 NH2 N CH 220.20 -1.241 106.30 3 7 0.83 0.84 323.2-325.1 200 
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Table 4.2: Physicochemical properties of SAR 1 Isoxazolidine-3-one imines (IZIs) 
 
Calculated physicochemical propertiesⱡ Experimental physicochemical properties 





H H 302.29 1.006 101.4 2 8 ND 264.20-265.10 200 
1.2 H H H 190.20 1.083 50.69 1 4 ND 209.10-210.10 40 
1.3 CH3 H H 204.23 1.464 50.69 1 4 ND 262.20-264.80 40 
1.4 CN H H 215.21 1.066 74.48 1 5 ND 221.90-226.80 80 
1.5 OCH3 H H 220.23 1.092 59.92 1 5 ND 303.0-305.70 80 
1.6 H OCH3 H 220.23 1.092 59.92 1 5 ND 303.10-305.70 200 
1.7 H H OCH3 220.23 1.092 59.92 1 5 ND 339.70-340.20 20 
1.8 H F H 208.19 1.209 50.69 1 4 ND 263.40-266.0 20 
1.9 F H H 208.19 1.209 50.69 1 4 ND 240.20-242.40 20 
1.10 H H F 208.19 1.209 50.69 1 4 ND 235.20-237.10 20 
1.11 Br H H 269.10 1.851 50.69 1 4 ND 282.20-283.40 40 
Abbreviations: MW = molecular weight; cLogP = calculated logarithm of n-octanol/water partition co-efficient; tPSA = topological polar surface area; HBD = 
hydrogen bond donor; HBA = hydrogen bond acceptors; Rf = retardation factor (thin layer chromatography, TLC), tR= retention time (high-performance 
liquid chromatography, HPLC); m.p = melting point; ND, not determined. ⱡCalculated using StarDrop©6; aanalytical TLC with 80% ethyl acetate in hexane, 




Overall, most of the predicted properties of compounds in the IZI and IZA series exhibited normal 
distribution profiles and this can be attributed to close similarities among analogues in each class. In 
contrast, the physicochemical properties of conventional anti-TB drugs and drug candidates were non-
normally distributed, because of the diverse classes making up each category. For effective statistical 
comparison, all physicochemical properties were considered to be non-normally distributed. 
Therefore, the calculated median values rather than the means were used as the basis of comparison 
and analysis. The use of the calculated median as a more robust variable was also supported by the 
small number of compounds in each class (n < 45). The calculated median values and ranges of each 
property across the various datasets are listed in Table 4.3. 
 
Table 4.3: Calculated median values for the predicted physicochemical parameters 
 
Property 
Calculated median values (range) 









































Abbreviations: IZIs = isoxazolidine-3-one-imines; IZAs = isoxazolidin-4-yl amides; TB.Ds = conventional anti-TB 
drugs; DCs = anti-TB drug candidates; MW = molecular weight; cLogP = calculated logarithm of n-octanol/water 
partition coefficient; tPSA = topological polar surface area; HBD = hydrogen bond donors; HBA = hydrogen bond 
acceptors.  
 
Calculated median values indicate that most of the compounds studied obeyed Lipinski’s RO5. 
However, the ranges reveal some degree of deviation, particularly with regard to properties 
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associated with TB.Ds and DCs, further highlighting the structural diversity of compounds in these 
classes. 
The non-parametric Mann-Whitney-Wilcoxon statistical comparison test was used as all compound 
sets were considered to have non-normal property distributions.13,14 This comparison was performed 
to establish whether or not there were any statistically significant differences between the predicted 
properties of IZIs and IZAs and those of TB.Ds and DCs. The test was performed by comparing all the 
predicted properties of a pair of independent compound sets and determining the p-value at a 95% 
confidence level. The null hypothesis (Ho) for the Mann-Whitney-Wilcoxon comparison was that there 
was no significant statistical difference in the distribution and the mean values of the compared 
datasets, when the significant value was 0.05. Therefore, the null hypothesis was rejected in all cases 
of p < 0.05 and accepted when p ≥ 0.05. Thus, there was no statistically significant difference between 
the parameters compared (Table 4.4). 
 
Table 4.4: Mann-Whitney-Wilcoxon test results (p-value) comparing differences between the predicted 
physicochemical properties of IZIs and IZAs versus those of TB.Ds and DCs 
Abbreviations: IZIs = isoxazolidine-3-one-imines; IZAs = isoxazolidin-4-yl amides; TB.Ds = conventional anti-TB 
drugs; DCs = anti-TB drug candidates; MW = molecular weight; cLogP = calculated logarithm of n-octanol/water 
partition coefficient; tPSA = topological polar surface area; HBD = hydrogen bond donors; HBA = hydrogen bond 
acceptors. Values in red (p < 0.05) indicate the null hypothesis was rejected at the significance level (that is, 
there is a difference in the compared datasets). 
 
Consequently, significant differences between IZIs and TB.Ds with respect to MW were revealed. 
However, IZIs and DCs showed similar properties except with regard to MW and tPSA. IZAs differed 
from TB.DS in terms of MW, and with regard to MW, tPSA, and HBA when compared to DCs. Frequency 
distribution histograms were plotted (Figures 4.1 and 4.2). As depicted in Figure 4.1A, 82% of IZIs had 
MWs between 150 and 350 Da, while 80% of IZAs had MWs <300 Da. In contrast, 54% of TB.Ds and 
 p-values  
MW cLogP tPSA HBD HBA 
IZIs vs TB.Ds 0.040 0.387 0.101 0.201 0.067 
IZIs vs DCs 0.012 0.169 0.037 0.202 0.018 
IZAs vs TB.Ds          0.015 0.474 0.080 0.168 0.051 
IZAs vs DCs 0.014 0.824 0.014 0.145 0.004 
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30% of DCs had MWs <400 Da. However, considering the RO5, 22% of TB.Ds and 28% of DCs had MWs 
>500 Da, whereas all IZIs and IZAs had MWs <500 Da. 
Significant differences in cLogP were observed between compound sets (Figure 4.1B and Table 4.4). 
Although 46%, 30%, and 49% of TB.Ds, DCs, and IZA, respectively, had cLogP < 1.0, none of the IZI 
analogues had cLogP values in this range (Figure 4.1B). Therefore, TB.Ds displayed uniquely lower 
cLogP values compared to the other clusters. cLogP values for all IZIs lay between 1.01 and 2.00, 
whereas only 20% of TB.Ds and 13% of DCs exhibited cLogP values in this range. In addition, 50% of 
IZAs had cLogP values in the range of 0.01 to 1.00. Lipinski’s RO5 was violated (cLogP > 5) by 6% and 
20% of TB.Ds and DCs, respectively (Figure 4.1B).  
To visualize the various chemical spaces (with respect to MW and cLogP) occupied by the four 
compound sets, cLogP values were plotted against MW (Figure 4.1C). The plot revealed that TB.Ds, 
IZIs, and IZAs all occupied similar chemical spaces. In this case, 60% of TB.Ds showed cLogP < 2 and 
MW < 400 Da. TB.Ds outside this space belonged mainly to two classes of compounds: rifamycins and 
aminoglycosides. All IZIs showed cLogP < 2 and MW < 350 Da, and 67% of IZAs displayed cLogP < 0 and 
MW < 300 Da. Conversely, DCs occupied a unique chemical space that is distinct from that occupied 
by TB.Ds, IZAs, and IZIs. In this regard, 44% of DCs had MWs ranging from 300 to 450 Da and cLogP 
between 1.0 and 3.0. Notably, the most recently approved anti-TB drugs, bedaquiline and delamanid, 
occupy a chemical space similar to that of compound libraries produced via similar approaches in the 





Figure 4.1: Frequency distribution histograms for A. molecular weight and B. calculated logarithm of n-octanol/water partition coefficient (cLogP). C. Scatter Plot showing 
the chemical space occupied by the compound sets studied with respect to molecular weight and cLogP. Abbreviations: IZI = isoxazolidine-3-one-imines; IZA = isoxazolidin-




Incorporation of hydrogen bonding moieties is a strategy commonly employed to improve aqueous 
solubility and facilitate drug-target binding interactions at the sub-cellular active sites. However, a 
high number of HBDs and HBAs may limit the permeation of compounds across lipid-rich cell 
membranes. Lipinski’s RO5 suggests that there should be ≤5 HBDs and ≤10 HBAs in an oral drug-like 
compound. The total number of HBAs and HBDs significantly affects the tPSA of a compound, which 
in turn influences its solubility and permeability. According to Veber et al., the combined number of 
HBDs and HBAs in a drug-like compound should be ≤12, and the tPSA should be ≤140 Å2.9 
In this study, most compounds exhibited tPSA values between 50 and 130 Å2 (Figure 4.2A), thus in 
agreement with Veber’s rule. Notably, injectable aminoglycosides as well as the orally administrated 
rifamycins exhibited relatively high tPSA values. It was also noted that all HBD distributions were 
skewed to the left (Figure 4.2B). For example, 90% of IZIs comprised one HBD while 66% of IZAs 
contained two. In contrast, 20% of TB.Ds and 10% of DCs had >5 HBDs and were thus in violation of 
the RO5. All compound sets exhibited normal distributions of HBAs, with values ranging from 0 to 8 
(Figure 4.2C). Approximately 20% of TB.Ds (primarily rifamycins and aminoglycosides) had >14 HBAs. 
Overall, most compounds in this study occupied a similar chemical space with regards to tPSA (<140 
Å2) and the total number of HBDs and HBAs (<15; Figure 4.3). This plot also highlighted a strong linear 
correlation between tPSA and the total number of HBDs and HBAs across all four compounds sets, 




Figure 4.2: Frequency distribution histograms of A. topological surface area (tPSA), B. distribution of hydrogen bond donor (HBDs), and C. hydrogen bond acceptors (HBAs). 
Abbreviations: IZIs = isoxazolidine-3-one-imines; IZAs = isoxazolidin-4-yl amides; TB.Ds = conventional anti-TB drugs; DCs = anti-TB drug candidates 
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Figure 4.3: Plot showing the chemical space occupied by the compound sets studied with respects to tPSA and 
the total number of hydrogen bond donors (HBDs) and hydrogen bond acceptors (HBAs) 
 
4.4 HPLC-based solubility versus kinetic solubility 
There are differences in the results obtained using the turbidimetric and HPLC-based methods across 
the IZI and IZA series (Figure 4.4), and it is evident that the turbidimetric assay unsurprisingly yields 
higher solubility values than HPLC-based method. 
 
 
Figure 4.4: Line graph comparing solubility results using the turbidimetric assay and the high-performance liquid 

























The turbidimetric assay yielded higher values than the HPLC-based method for 14 of the 16 
compounds tested. This discrepancy may in part be attributed to the shorter incubation period in the 
turbidimetric method, with the measurements thus obtained in a saturated solution rather than a 
solution that has reached equilibrium.14,15 In addition, the turbidimetric and HPLC assay differ with 
regard to the precipitate formed at equilibrium (amorphous or crystalline), as solubility is influenced 
by the solid-state form of a compound. Additionally, solubility values obtained may only be estimated 
in contrast to determination of the exact compound concentration in solution.  
Generally, the turbidimetric method favors the formation of an amorphous precipitate due to the 
presence of DMSO whereas in the HPLC-based method, the form that is more energetically efficient 
is favored due to the long incubation time and absence of DMSO. If an amorphous solid precipitates 
in the HPLC-based assay, the results are likely to be closer to those of the turbidimetric method than 
if a crystalline precipitate is formed.16 
Considering that the HPLC-based method is more rigorous, SPR analysis of the IZI and 3-IZA series was 
performed using the HPLC-based solubility results. 
 
4.5 Structure-property relationships (SPRs) 
Solubility plays a key role in drug discovery as it provides information for diverse research activities 
such as biological activity assessments, structure optimization, pharmacokinetic (PK) screening, and 
animal dosage form selection for efficacy, PK, and toxicity screening.17 Therefore, it is essential to 
establish the solubility of potential drug candidates in the early stages of the drug discovery 
process15,18 as this indicates how a drug molecule is likely to perform in subsequent in vitro assays, and 
may suggest possible problems with regard to ADME.11 Poorly soluble compounds may precipitate out 
of solution during biological tests, thus leading to poorly reproducible and unreliable in vitro and in 
vivo study results.19 Although solubility is a measurable parameter, the values obtained vary as they 
are dependent on solvent factors (pH, temperature, and co-solvent effects) and experimental 
conditions (time, detection method, and assay materials) at the time of measurement.12,15  
Although the majority of compounds in the IZI series exhibited very low solubility (<11 μM) and those 
in the IZA series exhibited high (>150 μM) aqueous solubility, the aim was to decipher the factors 
affecting solubility. Factors responsible for improved solubility were deduced by measuring properties 
that are inherent and dependent on a compound’s structural features. Accordingly, melting points 
were measured to provide information about crystal packing energies, tPSA was used as a relative 
estimate of polarity, while cLogP values were generated in silico and used as a measure of lipophilicity. 
To investigate the relationship between these factors and aqueous solubility across a particular class 
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of compounds, correlation graphs of aqueous solubility were plotted against the appropriate factor 
for each class of compounds and the correlation strength (R2) was determined using Evans’ guidelines 
as follows:20 




0.8-1.00: Very strong 
 
These plots revealed a very strong correlation between solubility and melting point in the IZA series 
(R2 = 0.9318; Figure 4.5C), suggesting that the crystal packing efficiency of the compounds in crystal 
lattices was more dominant than changes in lipophilicity or polarity. In contrast, the IZI series showed 
moderate correlations between solubility and tPSA (Figure 4.5B). This may suggest that increasing the 
polarity of compounds in the IZI series led to improved aqueous solubility. There was no correlation 
between solubility and cLogP (lipophilicity) in either class of compounds (R2 = 0.085 for IZIs and R2= 























This chapter described the studies conducted with respect to physicochemical profiling. This revealed 
that IZA, IZI and TB.Ds(with the exception of injectable aminoglycosides, Rifamycins and clofazimine) 
occupy very similar chemical spaces[Mwt and cLogP], which are distinct from that occupied by a 
majority of the anti-TB drugs candidates. There were minor violations of the Lipinski’s RO5 was 
observed. In addition to this, SPR studies showed that solubility was strongly correlated to melting 
point in the IZA series (R2 = 0.9318) and moderately correlated to tPSA for IZI(R2 = 0.164, whereas there 
was no correlation between solubility and cLogP (lipophilicity) in either class of compounds (R2 = 0.085 
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Chapter 5: Conclusions and recommendations for future work 
 
5.1 Summary and conclusions 
The overall objective of this study was to conduct structure-activity relationships towards identifying 
new analogues of DCS with improved selective antimycobacterial activity. This was based on the 
hypothesis that the relatively safer DCS analogue Terizidone displayed enhanced antimycobacterial 
activity. 
The first aim of the study was to design, synthesize and characterize new isoxazolidine-3-one-imines 
and 3-isoxazolidin-4-yl amides. All compounds were fully characterized using spectroscopic 
techniques (NMR spectroscopy); chromatographic methods (TLC and HPLC-MS) and physicochemical 
attributes (melting point, and aqueous solubility). 
The second aim of the study was to pharmacologically evaluate the synthesized compounds for their 
in vitro antimycobacterial activity, cytotoxicity and microsomal metabolic stability. Two compounds 
(1.1 and 3.3) out of the 16 novel compounds displayed antimycobacterial potency against the drug-
susceptible Mtb H37Rv strain cultured in 7H9/ADC media. Furthermore all 17 compounds exhibited 
low cytotoxicity against the CHO and HepG2 cell lines. The most potent compound, 3.3, exhibited high 
microsomal metabolic stability across all species. 
The third aim of the study was to profile all final target compounds with respect to physicochemical 
properties, including aqueous solubility. The HPLC-based solubility data obtained was correlated with 
the experimentally determined melting points, HPLC retention times (tR), TLC retardation factors (Rf) 
as well as the virtually predicted physicochemical properties such as cLogP, in order to establish 
structure-property relationships. It was observed that, solubility was strongly correlated to melting 
point in the IZA series (R2 = 0.9318) and moderately correlated to tPSA for IZI (R2 = 0.164), whereas 
there was no correlation between solubility and cLogP (lipophilicity) in either class of compounds (R2 








5.2 Recommendations for future work  
I. Study the mechanism of action and resistance of selected active compounds using tool 
mycobacterial strains and/or metabolic rescue or biochemical assays. 
II. Since compound 3.3 (as shown below) displayed good activity, low cytotoxicity, high 
metabolic stability, this compound should be progressed to in vivo pharmacokinetics and for 
efficacy studies in a mouse model of TB. 
 
Compound 3.3 



























Chapter 6: Experimental results 
 
6.1 Chapter overview 
The results related in Chapter 5 supplement those discussed in Chapters 2-4 by describing the 
experimental protocols involved, particularly those that are not outlined in the main text. In addition, 
the characterization data of all the synthesized compounds are provided in this chapter. 
 
6.2 Methods: Chemistry 
6.2.1 Reagents and solvents 
All commercially available chemicals were purchased from Sigma-Aldrich or Combi-Blocks with the 
exception of 5-((tert-butoxycarbonyl)amino)picolinic acid, which was purchased from FluroChem, UK. 
All commercially available reagents were of analytical grade (AR) and were thus used without 
purification. N,N-Dimethylformamide (DMF) and methanol were purchased as anhydrous solvents 
whereas all other commonly used solvents were purchased from Science World. The high-
performance liquid chromatography (HPLC)-grade solvents ammonium acetate and MeOH were 
obtained from Sigma-Aldrich for use in chromatography and mass spectrometry (MS).  
 
6.2.2 Spectroscopic and physical characterization 
NMR: 1H-NMR spectra were recorded on Varian Mercury (300 MHz), Brucker Ultrashield-Plus Varian 
Mercury (400 MHz), or Bruker (600 MHz) instruments with tetramethylsilane (TMS) as the internal 
reference. 13C-NMR spectra were recorded on the same instruments at 101 MHz or 151 MHz with TMS 
as the internal standard. 13C chemical shift values are listed without specific assignment to carbon 
atoms. NMR samples were dissolved in deuterated dimethylsulfoxide (DMSO-d6). Chemical shifts (δ) 
are reported in parts per million (ppm) to two decimal places and coupling constants (J) are reported 
in Hertz (Hz) to two decimal places. Abbreviations used in assigning in 1H-NMR signals are: d (doublet), 
dd (doublets of doublets), ddd (doublets of doublets of doublets), m (multiplet), q (quartet), s (singlet), 
t (triplet), or td (triplets of doublets). Where assignment of 1H-NMR and 13C-NMR signals was 
ambiguous, two-dimensional NMR spectra from correlation spectroscopy (COSY) and heteronuclear 




Melting points: Melting points were measured using the Stuart automatic melting point apparatus 
SMP40 and are reported as uncorrected values. The recorded melting points were measured in 
duplicate and represent the average of the clear point, which is the temperature at which all solid 
materials in the melting tubes turns to liquid. 
 
6.2.3 Chromatography  
The peak purity, retention time, and molecular ions of the target compounds were determined using 
an Agilent HPLC-MS instrument with Agilent 1260® Infinity binary pump, Agilent 1260® Infinity diode 
array detector, Agilent 1290® Infinity column compartment, Agilent 1260® Infinity autosampler, 
Agilent 6120® quadrupole LC/MS, and Peak Scientific® Genius 1050 nitrogen generator. An X-bridge® 
(C18, 2.5 µm, 3.0 mm (ID) x 50 mm length) column maintained at 35 °C was used. The composition 
and gradient conditions of the mobile phase used at a flow rate of 0.9 mL/min with 2 µL injection 
volume are listed in Table 5.1. The mass spectra were acquired using electrospray ionization (ESI) or 
atmospheric pressure chemical ionization (APCI) in positive and negative ionization modes. All final 
compounds with the exception of compounds 1.1-1.11 were subjected to purity check experiments 
using LC-MS to ensure purity was ≥95%. 










Mobile phase A, 10 mM NH4OAc in buffer (0.4% acetic acid); mobile phase B, 10 mM NH4OAc (0.4% acetic acid) 
in 90% HPLC-grade CH3OH in H2O. HPLC-MS, high-performance liquid chromatography-mass spectrometry. 
 
Reaction progress was monitored using a combination of analytical thin-layer chromatography (TLC) 
and LC-MS. TLC Silica gel 60 F254 aluminium-backed, pre-coated silica gel plates were purchased from 
Merck. Spots were visualized using ultra-violet (UV) light at 254 or 366 nm and non-UV-absorbing TLC 
spots were visualized using ninhydrin or anisaldehyde spray. TLC plates were developed to monitor 
reaction progress and accurately determine retardation factor values (Rf) in a 100-mL beaker covered 
with a watch glass. Silica gel column chromatography was performed using Merck Kieselgel 60: 70-
Time (min) 
% A % B 
0.00-1.00 90 10 
1.00-3.00 5 95 
3.00-5.00 5 95 
5.00-6.50 90 10 
6.50-7.00 90 10 
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230 mesh (gravity column or flash chromatography) on a Biotage IsoleraTM system (Biotage, AB, 
Uppsala, Sweden). 
6.2.4 Synthesis and characterization 
General procedure for the synthesis of SAR 1 compounds 1.1-1.11 
The relevant aldehyde (1.0 equiv) was dissolved in 2-4 mL of methanol. The solution was heated under 
reflux at 65 ᵒC for 5 min. Subsequently, a suspension of D-cycloserine (1.5 equiv) in 5 mL methanol 
was added to the solution and left to reflux until the solution became milky white/turbid. The solution 
was rapidly cooled down and left to stir under ice for 2-3 h until a precipitate form. The precipitate 














     
 









Obtained from terephtalaldehyde (0.250 g, 1.86 mmol, 
1.0 equiv) and D-cycloserine (0.383 g, 3.72 mmol, 3 
equiv) as a white solid (0.221 g, 88%); m.p 264.2-265.1 
ᵒC; δH (400 MHz, DMSO-d6): 11.42 (s, 2H, 2x NH-1), 8.51 
(s, 2H, 2x H-4), 7.84 (s, 4H, 4x H-5), 4.66 (dd, J = 8.57, 
7.35 Hz, 2H, 2x H-2a), 4.55 (t, J = 7.28 Hz, 2H, 2x H-3), 
4.39 (dd, J = 8.58, 7.12 Hz, 2H, 2x H-2b); δc (101 MHz, 
DMSO-d6) 170.54 (2C), 164.70 (2C), 138.37 (2C), 128.95 
(4C), 74.56 (2C), 70.18 (2C). 
 
Obtained from benzaldehyde (0.200 g, 1.87 mmol, 1.0 
equiv) and D-cycloserine (0.290 g, 2.83 mmol, 1.5 
equiv) as a white solid (0.070 g, 20%); m.p 209.1-210.1 
ᵒC; δH (400 MHz, DMSO-d6), δ 8.34 (s, 1H, NH-1), 8.25 
(s, 1H, H-4), 7.62-7.50 (m, 2H, 2x H-5), 7.43-7.38 (m, 
3H, 2x H-6, H-7), 4.46-4.30 (m, 2H, H-2a, H-2b); δC (101 
MHz, DMSO-d6) δ 165.41, 150.26, 132.16, 130.57, 



































Obtained from p-tolualdehyde (0.250 g, 2.08 mmol, 1.0 
equiv) and D-cycloserine (0.321 g, 3.12 mmol, 1.5 equiv) 
as a white solid (0.150 g, 35%); m.p 262.20-264.8 ᵒC; δH 
(400 MHz, DMSO-d6): 8.18 (s, 1H, NH-1), 8.14 (s, 1H, H-
4), 7.47 (d, J = 8.13 Hz, 2H, 2x H-5), 7.20 (d, J = 8.1 Hz, 
2H, 2x H-6), 4.40-4.30 (m, 2H, H-2a,H-2b), 4.18-4.13 (m, 
1H, H-3), 2.31 (s,3H, 3x H-7); δC (101 MHz, DMSO-d6): 
165.46, 150.18, 140.33, 133.40, 129.78 (2C), 127.46 
(2C), 75.37, 55.27, 21.38 
 
C 
Obtained from 4-cyanobenzaldehyde (0.250 g, 1.90 
mmol, 1.0 equiv) and D-cycloserine (0.294 g, 2.85 
mmol, 1.5 equiv) as a white solid (0.031 g, 9.5%); m.p 
221.9-226.8 ᵒC; δH (400 MHz, DMSO-d6): 8.40 (s, 1H, 
NH-1), 8.34 (s, 1H, H-4), 7.86 (d, J = 8.40 Hz, 2H, 2x H-
5), 7.79 (d, J = 8.39 Hz, 2H, 2x H-6), 4.4-4.38 (m, 2H, H-
2a, H-2b), 4.22-4.18 (m, 1H, H-3); δC (101 MHz, DMSO-
d6): 165.31, 149.05, 136.62, 133.15 (2C), 128.10 (2C), 
118.96, 112.65, 75.65, 55.06. 
 
Obtained from p-anisaldehyde (0.200 g, 1.46 mmol, 1.0 
equiv) and D-cycloserine (0.226 g, 2.20 mmol, 1.5 equiv) 
as a white solid (0.023 g, 7.5%); m.p 303.0-305.7 ᵒC; δH 
(400 MHz, DMSO-d6): 8.31 (s, 1H, NH-1), 8.18 (s, 1H, H-
4), 7.54 (d, J = 8.85 Hz, 2H, 2x H-5), 6.96 (d, J = 8.78 Hz, 
2H, 2x H-6), 4.38-4.32 (m, 2H, H2a, H-2b), 4.18-4.14 
(m,1H, H-3), 3.78 (s,3H, 3x H-7); δC (101 MHz, DMSO-d6): 
165.31, 149.05, 136.62, 133.15 (2C), 128.10 (2C), 




































Obtained from m-anisaldehyde (0.200 g, 1.46 mmol, 
1.0 equiv) and D-cycloserine (0.226 g, 2.20 mmol, 1.5 
equiv) as a white solid (0. 014 g, 4.3%); m.p 303.1-
305.7 ᵒC; δH (400 MHz, DMSO-d6): 8.34 (s, 1H, NH-1), 
8.21 (s, 1H, H-4), 7.34-7.32 (m, 1H, H-6), 7.18-7.16 (m, 
2H, H-5, H-6), 6.98 (ddd, J = 8.26, 2.60, 1.70 Hz, 1H, H-
8) 4.44-4.39 (m, 2H, H-2a, H-2b), 4.18-4.16 (m, 1H, H-
3), 3.76 (s, 3H, 3x H-9); δC (101 MHz, DMSO-d6): 175.00, 
163.84, 159.93, 133.51, 130.34, 120.07, 116.57, 
112.26, 75.66, 55.65, 55.09.  
 
 
Obtained from o-anisaldehyde (0.200 g, 1.46 mmol, 1.0 
equiv) and D-cycloserine (0.226 g, 2.20 mmol, 1.5 equiv) 
as a white solid (0.151 g, 46%); m.p 339.7-340.2 ᵒC; δH 
(400 MHz, DMSO-d6): 8.38 (s, 1H, NH-1), 8.35 (s, 1H, H-4), 
7.63 (dd, J = 7.66, 1.72 Hz, 1H, H-5), 7.40 (ddd, J = 8.35, 
7.52, 1.81 Hz, 1H, H-7), 7.06 (d, J = 8.35 Hz, 1H, H-8), 6.95 
(dd, J = 8.79, 7.66 Hz, 1H, H-6), 4.38-4.28 (m, 2H, H-2a, H-
2b), 4.18-4.13 (m, 1H, H-3), 3.76 (s, 3H, 3x H-9); δC (101 
MHz, DMSO-d6) 165.85, 165.37, 157.76, 145.69, 132.20, 
126.48, 121.10, 112.32, 75.36, 56.16, 54.32 
 
Obtained from 4-flurobenzaldehyde (0.200 g, 1.61 mmol, 
1.0 equiv) and D-cycloserine (0.248 g, 2.41 mmol, 1.5 
equiv) as a white solid (0.138 g, 41%); m.p 263.4-266.0 
ᵒC; 1H-NMR (400 MHz, DMSO-d6) δ 8.33 (s, 1H, NH-1), 
8.25 (s, 1H, H-4), 7.65 (ddd, J = 8.71, 5.40, 2.58 Hz, 2H, 2x 
H-5), 7.23 (ddd, J = 8.89, 5.32, 2.58 Hz, 2H, 2x H-6), 4.43-
4.32 (m, 2H, H2a, H2b), 4.17-4.13 (m, 1H, H3); δC (101 
MHz, DMSO-d6): 174.98, 165.40, 164.80, 149.21, 129.69 
(d, J = 8.50 Hz, 2C), 116.31 (d, J = 22.01 Hz, 2C), 75.53, 



































Obtained from 3-flurobenzaldehyde (0.200 g, 1.61 mmol, 
1.0 equiv) and D-cycloserine (0.248 g, 2.41 mmol, 1.5 
equiv) as a white solid (0.016 g, 4.95%); m.p 240.2-242.4 
ᵒC; δH (400 MHz, DMSO-d6): 8.38 (s, 1H, NH-1), 8.35 (s, 1H, 
H-4), 7.50-7.38 (m, 2H, H H-7, H-8), 7.43-7.39 (m, 1H, H5), 
7.30-7.22 (m, 1H, H-6), 4.45-4.31 (m, 2H, H-2a, H-2b), 4.20-
4.16 (m, 1H, H-3); δC (101 MHz, DMSO-d6): 163.91, 161.49, 
134.61 (d, J = 8.29 Hz), 131.32 (d, J = 8.34 Hz), 123.80, 
117.33 (d, J = 21.37 Hz), 113.66 (d, J = 22.69 Hz), 75.49, 
55.08; 19F (377 DMSO-d6) δ -112.74.    
 
Obtained from 2-flurobenzaldehyde (0.200 g, 1.61 mmol, 
1.0 equiv) and D-cycloserine (0.248 g, 2.41 mmol, 1.5 
equiv) as a white solid (0.151 g, 49%); m.p 235.2-237.1 ᵒC; 
δH (400 MHz, DMSO-d6) 8.39 (s, 1H, NH-1), 8.32 (s, 1H, H-
4), 7.72 (dd, J = 7.60, 1.83 Hz 1H, H-5), 7.52-7.43 (m, 1H, 
H-7), 7.27 (dd, J = 7.87, 7.35 Hz, 1H, H-6), 7.22 (d, J = 6.90 
Hz, 1H, H-8) 4.44-4.32 (m, 2H, H-2a, H-2b), 4.24-4.15 (m, 
1H, H-3); δC (101 MHz, DMSO-d6) 165.85, 161.81, 159.32, 
132.68 (d, J = 8.58 Hz), 127.68, 125.29, 119.61 (d, J = 10.67 
Hz), 116.52 (d, J = 20.68 Hz), 76.87, 55.07; δF (377 DMSO-
d6) δ -118.60.    
 
Obtained from 4-bromobenzaldehyde (0.200 g, 0.74 
mmol, 1.0 equiv) and D-cycloserine (0.114 g, 1.11 mmol, 
1.5 equiv) as a white solid (0.082 g, 28%); m.p 282.2-
283.4 o C; δH (400 MHz, DMSO-d6) 8.26 (s, 1H, NH-1), 8.24 
(s, 1H, H-4), 7.61 (d, J = 8.65 Hz, 2H, 2x H-5), 7.54 (d, J = 
8.50 Hz, 2H, 2x H-6), 4.47-4.31 (m, 2H, H-2a, H-2b), 4.19-
4.16 (m, 1H, H-3); δC (101 MHz, DMSO-d6) 167.3, 165.38, 





General procedure for compounds 3.1 and 3.6  
For compound 3.1, a solution containing D-CS (1.2 equiv) was added to the relevant acyl chloride (1.0 
equiv) and was treated with triethylamine (1.5 equiv) in N-methyl-2-pyrrolidone (NMP). For 
compound 3.6, twice the equivalence of D-CS and triethylamine was used. The reaction was left to stir 
at room temperature (18–20 °C) for 1–1.5 h. The solvent was removed using a GeneVac evaporator. 
The crude product was then purified via column chromatography on silica gel using 80% EtOAc/Hex 
to produce a white solid. 
 






















Obtained from benzoyl chloride (0.300 g, 2.13 mmol, 1.0 
equiv), D-cycloserine (0.264 g, 2.56 mmol, 1.2 equiv) 
treated with triethylamine (0.44 mL, 1.5 equiv) as a white 
solid (54.7 mg, 19%); m.p. 187.3–186.6 ᵒC; Rf (EtOAc: Hex, 
8:2) 0.13; δH (400 MHz, DMSO-d6): 11.49 (s, 1H, H-1), 8.92 
(d, J = 8.21 Hz, 1H, H-4), 7.87 (dd, J = 7.06, 1.42 Hz, 1H, 2x 
H-5), 7.54 (dd, J = 6.90, 1.42 Hz, 1H, 2x H-7), 7.48 (dd, J = 
8.32, 6.90 Hz, 2H, 2x H-6), 5.04 (q, J = 9.23 Hz, 1H, H-3), 
4.57 (t, J = 8.53 Hz, 1H, H-2b), 4.11 (dd, J = 10.36, 8.28 Hz, 
1H, H-2a); δC (101 MHz, DMSO-d6): 170.54, 166.38, 133.50, 
131.51, 128.26 (2C), 127.29 (2C), 71.70, 51.44; HPLC-MS 
(APCI/ESI): purity = 96%, tR = 0.45 min, m/z [M+H]+= 
207.07. 
Obtained from terephthaloyl dichloride (0.200 g, 0.99 
mmol, 1.0 equiv), D-cycloserine (0.201 g, 1.97 mmol, 2.0 
equiv) treated with triethylamine (0.41 mL, 3 equiv) as a 
white solid (47.2 mg, 14%); m.p. 366.1–368.2 ᵒC; Rf 
(MeOH: DCM) 0.08; δH (400 MHz, DMSO-d6): 11.51 (s, 2H, 
H-1), 9.08 (d, J = 8.21 Hz, 2x H-4), 7.97 (s, 4H, 4x H-5), 5.05 
(q, J = 9.06 Hz, 2H, 2x H-3), 4.58 (t, J = 8.57 Hz, 2H, 2x H-
2b), 4.12 (dd, J = 10.23, 8.36 Hz, 2H, 2x H-2a); δC (101 MHz, 
DMSO-d6) 170.88 (2C), 166.40 (2C), 136.76 (2C), 127.88 
(4C), 72.43 (2C), 52.28 (2C); HPLC-MS (APCI/ESI): purity > 
99%, tR = 0.29 min, m/z [M+H]+ = 335.09. 
 
 




General procedure for compounds 3.2 and 3.3  
The relevant carboxylic acid was solubilized in thionyl chloride (3.0 equiv). The solution was heated 
under reflux at 85.5 °C and the solvent was removed under reduced pressure, yielding the relevant 
crude acyl chloride, which was used without purification. The relevant acyl chloride (1.0 equiv) was 
solubilized into a solution of D-CS (1.2 equiv) and triethylamine (1.5 equiv) in DMF. The reaction was 
left to stir at room temperature (18–20 °C) for 1–1.5 h. DMF was removed in vacuo and the resulting 
crude mixture was purified via silica gel chromatography using the relevant solvent system. Combined 
fractions were concentrated in vacuo and dried under the vacuum to yield the relevant target 
compounds 3.2-3.3. 
 






















Obtained from 4-bromobenzoyl chloride (0.300 g, 1.37 
mmol, 1.0 equiv), D-cycloserine (0.168 g, 1.64 mmol, 1.2 
equiv) treated with triethylamine (0.38 mL, 1.5 equiv) 
using 80% EtOAc/Hex as a eluent to afford a white solid 
(20.8 mg, 5.33%); m.p 317.4–313.8 o C; Rf (EtOAc: Hex, 8:2) 
0.14; δH (400 MHz, DMSO-d6) 11.49 (s, 1H, H-1), 9.02 (d, J 
= 8.19 Hz, 1H, H-4), 7.82 (d, J = 8.63 Hz, 2H, 2x H-5), 7.70 
(d, J = 8.57 Hz, 2H, 2x H-6), 5.05-4.99 (m, 1H, H-3), 4.57 (t, 
J = 8.6 Hz, 1H, H-2b), 4.10 (dd, J = 10.2, 8.4 Hz, 1H, H-2a); 
δC (101 MHz, DMSO-d6): 166.03, 133.16, 131.94 (2C), 
129.98 (2C), 125.87, 72.25, 52.07; HPLC-MS (APCI/ESI): 
purity = 96%, tR = 0.75 min, m/z [M+H]+ = 284.9, 285.9, 
286.9, 287.9. 
Obtained from 4-methoxybenzoyl chloride (0.300 g, 1.758 
mmol, 1.0 equiv), D-cycloserine (0.217 g, 2.113 mmol, 1.2 
equiv) treated with triethylamine (0.61 mL, 1.5 equiv) 
using 90% EtOAc/Hex as a eluent to afford a white solid 
(20 mg, 21%); m.p 315.2–317.8 ᵒC; Rf (EtOAc: Hex, 8:2) 
0.13; δH (400 MHz, DMSO-d6), 11.44 (s, 1H, H-1), 8.74 (d, J 
= 8.08 Hz, 1H, H-4), 7.87 (d, J = 8.88 Hz, 2H, 2x H-5), 7.02 
(d, J = 8.87 Hz, 2H, 2x H-6), 5.06-4.93 (m, 1H, H-3), 4.54 (t, 
J = 8.6 Hz, 1H, H-2b), 4.20-4.08 (m, 1H, H-2a), 3.81 (s, 3H, 
3X H-7); δC (101 MHz, DMSO-d6): 166.37, 165.40, 162.36, 
159.68, 129.75 (2C), 114.05 (2C), 72.33, 55.86, 55.10; 
HPLC-MS (APCI/ESI): purity > 99%, tR = 0.57 min, m/z 




General procedure for compound 3.4 
Pyrazine-2-carboxylic acid (1 equiv) was solubilized in thionyl chloride (3.0 equiv). The solution was 
heated under reflux at 85.5 ᵒC. Thionyl chloride was removed under pressure, yielding pyrazine-2-
carbonyl chloride, which was used without further purification. Pyrazine-2-carbonyl chloride was 
solubilized into a solution of D-CS (1.2 equiv) and triethylamine (2.5 equiv) in DMF. The reaction was 
left to stir at room temperature (24–26 ᵒC) for 1–1.5 h. DMF was removed in vacuo and the resulting 
crude mixture was dry-loaded on ISOLUTE® and purified using a reversed-phase ISCO CombiFlash 
system eluting with a gradient (0 to 10%, 0.1% formic acid in acetonitrile and 0.1% trifluoroacetic acid 
(TFA) in water). The combined pure fractions were concentrated in vacuo and dried under vacuum to 
yield the relevant target compound 3.4. 
 










General procedure for compound 3.5 
5-((Tert-butoxycarbonyl)amino)picolinic acid (1 equiv) was added to a solution of 1,1'-
carbonyldiimidazole (CDI, 2.5 equiv) in DMF and the resulting mixture was stirred for 1 h at 18 ᵒC. In a 
separate round-bottom flask, D-CS (2.5 equiv) was added to a catalytic amount of 4-
dimethylaminopyridine (DMAP) in DMF and the resulting mixture was left to stir for 5 min. The 
solution containing D-CS was added dropwise to the flask containing the acid and the resulting mixture 
was stirred at 18–20 ᵒC for 20 h. After completion of the reaction (monitored via TLC), DMF was 
removed in vacuo and the resulting crude mixture was purified via column chromatography (15% 




Obtained from pyrazine-2-carboxylic chloride (0.800 g, 5.61 
mmol, 1.0 equiv), D-cycloserine (0.686 g, 6.73 mmol, 1.2 
equiv) treated with triethylamine (1.19 mL, 1.5 equiv) as a 
white solid (247.0 mg, 21%); m.p. 313.5–318.2 o C; Rf (EtOH: 
DCM, 1:9) 0.63; δH (400 MHz, DMSO-d6) 11.55 (s, 1H, H-1), 
9.32 (d, J = 8.3 Hz, 1H, H-4), 9.20 (d, J = 1.46 Hz, 1H, H-5), 
8.90 (d, J = 2.43 Hz, 1H, H-6), 8.77 (dd, J = 2.43, 1.63 Hz, 1H, 
H-7), 5.06 (dt, J = 11.05, 8.57 Hz, 1H, H-3), 4.57 (t, J = 8.48 
Hz, 1H, H-2b), 4.25 (dd, J = 11.06, 8.17 Hz, 1H,H-2a); δC (101 
MHz, DMSO-d6) 170.65, 163.08, 148.34, 144.69, 144.02 
(2C), 71.78, 51.75; HPLC-MS (APCI/ESI): purity > 99%, tR = 














6.3 Methods: Biology 
6.3.1 Turbidimetric solubility 
The turbidimetric method described by Bevan and Lloyd1 was adapted to estimate the aqueous 
solubility of the final target compounds at pH 7.4. Stock solutions (10 mM) of target and control 
compounds (reserpine and hydrocortisone) were prepared in HPLC-grade DMSO. Subsequently, stock 
solutions were serially diluted in triplicate by first pipetting 20 μL DMSO into row G and 50 μL DMSO 
in the rows above (Figure 5.1). Next, 80 μL of the 10 mM stock solutions was pipetted into row G and 
mixed to obtain a starting concentration of 8 mM (100 μL). This solution was serially diluted by 
transferring 50 μL from row F through to row B. The final pre-dilution concentrations obtained ranged 
from 0.25 mM (row B) to 8.0 mM (row G). The wells in row A contained only DMSO, while those in 
row H contained the undiluted 10 mM stock solution. 
     Compound 1  Compound 2  Compound 3  Compound 4 
      (triplicate)     (triplicate)    (triplicate)    (triplicate)   
Conc.                                           1   2   3   4   5   6  7   8   9   10   11   12  (mM)                           
                                                                             
0 
 A                                     
                                      
0.25 
 B                                     
                                     
0.5 
 C                                     
                                     
1.0 
 D                                     
                                     
2.0 
 E                                     
                                     
4.0 
 F                                     
                                      
8.0 
 G                                     
                                     
10.0 
 H                                     
                                      
Figure 6.1: Layout of the turbidimetric solubility assay compound pre-dilution plate 
White solid (10.0 mg, 10%); m.p. 323.2–325.1 ᵒC; Rf 
(EtOH: DCM, 1:9) 0.54; δH (400 MHz, DMSO-d6) 9.91(s, 
1H, H-1), 8.66 (d, J = 8.3 Hz, 1H, H-4), 9.20 (d, J = 1.46 
Hz, 1H, H-5), 8.90 (d, J = 2.66 Hz, 1H, H-6), 8.05 (dd, J = 
8.48, 2.63 Hz, 1H, H-7), 4.98 (dt, J = 11.04, 8.05 Hz, 1H, 
H-3), 4.57 (t, J = 8.48 Hz, 1H, H-2b), 4.20 (dd, J = 11.13, 
8.09 Hz, 1H,H-2a); δC (101 MHz, DMSO-d6) 170.50, 
166.91, 160.74, 152.29, 149.72, 138.50, 132.42, 123.35, 
88.92, 67.52, 64.75, 59.30, 26.91 (3C); HPLC-MS 




From each pre-dilution solution, secondary dilutions were prepared in DMSO and 0.01 M phosphate 
buffered saline (PBS, pH 7.4) in a second 96-well microtiter plate in triplicate (Figure 5.2). Wells in 
columns 1-6 contained the test compound dissolved in DMSO while those in columns 7-12 contained 
the same compound dissolved in PBS. The final volume in each well was 200 μL, prepared by pipetting 
4 μL of each solution from the pre-dilution plate to the corresponding well into both DMSO and PBS 
(196 μL each). The final concentration of DMSO in the PBS aqueous buffer preparations was therefore 
2% v/v. Test compounds in DMSO served as controls to determine potential false turbidimetric 
absorbance readings arising from the compounds in solution absorbing radiation at the analysis 
wavelength. 
 
        DMSO      0.01 M PBS (pH 7.4)   
                   
    Compound 1 Compound 2 Compound 1 Compound 2 
     (triplicate)   (triplicate)   (triplicate)  (triplicate) 
Conc. (M) 
                      
   1 2  3 4 5  6 7 8  9 10  11 12 
                       
0  A                     
                       
5  B                     
                      
10  C                     
                       
20  D                     
                       
40  E                     
                      
80  F                     
                       
160  G                     
                       
200  H                     
                       
Figure 6.2: Turbidimetric solubility assay plate layout 
 
 
The plates were covered and left to equilibrate for 2 h at room temperature. UV-VIS absorbance 
values were then recorded at 620 nm using a SpectraMax 340PC384 microplate reader (Molecular 
Devices, Sunnydale, CA, USA). The wells containing only DMSO and 2% v/v DMSO in PBS (0 μM in plate 
layout, row A) served as controls and blanks. At concentrations above the solubility limit, undissolved 
particles precipitated out of solution, occluding incident radiation and resulting in increased apparent 
absorbance. Therefore, the concentration at which increased absorbance was recorded was 
considered to be the approximate solubility of the compounds. Reserpine and hydrocortisone were 
used as minimum and maximum solubility standards respectively, as established by previous reports.9 
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6.3.2 HPLC-based solubility 
Kinetic solubility measurements were obtained by Nina Lawrence at the Holistic Drug Discovery and 
Development centre (H3D). Aqueous solubility was measured using the DMSO dry-down method, 
adapted from Zhou et al.2,3 Briefly, the high and medium calibration standards (220 and 100 μM, 
respectively) were added in duplicate and samples (200 μM) were added in triplicate to a 96-well plate 
from a 10 mM stock solution in DMSO. DMSO was then evaporated in a MiVac sample concentrator 
(SP Scientific, Cape Town, South Africa) operated at full vacuum at 37 °C for 2 h. DMSO was then added 
to the standards and after vortexing the plate, the high standard was used to prepare a low (11 μM) 
calibration standard in DMSO. PBS (pH 7.4) was added to the sample wells and the plate was incubated 
for 24 h at 25 °C with shaking. The plate was then centrifuged at 2500 × g for 30 min and the 
supernatants were transferred to another plate for analysis. Aqueous solubility was determined from 
the UV peak areas of the samples relative to those of the standards using best-fit calibration curves in 
Microsoft Excel 2013. HPLC-DAD analysis was performed using an Agilent 1200 Rapid Resolution HPLC 
instrument, coupled with an Agilent 1200 diode array detector (ABSciex, Johannesburg, South Africa). 
For elution, 0.1% formic acid in water and 0.1% formic acid acetonitrile were used as mobile phases 
A and B, respectively. A Kinetex C18 (50 mm x 2.1 mm) column packed with 2.6-μM fused-core 
particles (Separations, Johannesburg, South Africa) was used for chromatography. Agilent 
Chemstation for used for instrument control and data processing. 
 
6.3.3 Bacterial strains and growth conditions 
For all antimycobacterial experiments carried out, M. smegmatis (Mc2155)4 (Msm) and M. tuberculosis 
H37Rv5 (Mtb) strains from stocks maintained at H3D at -80 oC were used. In the case of Msm, the 
stocks were stored in 33% glycerol (v/v). All culturing and manipulations of Mtb were performed by 
Tb biology team in a Biosafety Level 3 laboratory at IDM. For experiments carried out using ESKAPE 
pathogens, strains of Staphylococcus aureus, Acinetobacter baumannii, Klebsiella pneumoniae, and 











Table 6.1 : Bacterial strains used in this study  
Bacterial species strain Strain 
Mycobacterium smegmatis Non-virulent reference laboratory of Msm Mc2 155 
Mycobacterium tuberculosis Virulent reference laboratory strain of Mtb H37Rv ATCC 27294 
Staphylococcus aureus ATC 25923 
Acinetobacter baumannii ATCC 19606 
Klebsiella pneumoniae ATCC BAA-1705 
Escherichia coli ATCC 25922 
 
Mtb and ESKAPE Pathogens was cultured in Middlebrook 7H9 (Difco™) broth enriched with 10% oleic 
acid-dextrose-catalase (OADC), 0.5% glycerol, and 0.05% Tween® 80. Growth medium was were 
filtered using filtration flasks fitted with 0.22-µm filter membranes. M. smeg was cultured in liquid 
broth (LB) and were sterilized by autoclaving at 121 oC for 15 min. 
 
6.3.4 Antimycobacterial screening: minimum inhibitory concentration (MIC) of target 
compounds in Msm, Mtb, and ESKAPE pathogens 
The MICs of synthesized compounds were determined via broth microdilution method using the 
microplate Alamar Blue assay (MABA). This method allows determination of the MICs of compounds 
over a range of concentrations in a single 96-well microtiter plate.6 In the MABA assay, the metabolic 
activity of the cell is correlated with Alamar Blue reduction and the resulting change in colour from 
blue to pink and fluorescent allows for visual detection and fluorometric or colorimetric quantification. 
For the experiments reported here, growth and growth inhibition were assessed visually. Prior to the 
addition of Alamar Blue (at day 3 for Msm and day 7 for Mtb), growth and inhibition were assessed 
via visual inspection for pellet formation, while growth and inhibition were assessed via visual 
inspection for pellet formation only for the ESKAPE pathogens. 
As described in Standard lab operating protocols (SOPs), a 10-mL Mtb culture was grown to reach an 
OD600 of 0.6–0.7 and diluted to 1:500 (in the case of Mtb) and/or 1:1000 (in case of Msm or ESKAPE 
pathogens) in the relevant medium. In a 96-well microtitre plate, 50 µL of the relevant medium was 
added to all wells in rows 2–12. Target compounds were added to row 1 at a final concentration of 8 
× MIC90 (for compounds with pre-determined or estimated MIC values) and serially diluted (two-fold). 
This was achieved by transferring 50 μL of the liquid in row 1 to row 2 using a multichannel pipette 
and mixing. Subsequently, 50 μL of the liquid in row 2 was transferred to row 3 and mixed. The 
procedure was repeated until row 11, from which 50 μL was discarded to bring the final volume in 
these wells to 50 μL. In row 12, the relevant control (1 mg/mL) was added for maximal inhibition 
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before adding 50 μL diluted culture was added to all wells. The microtitre plate was stored in a 
secondary container and incubated at 37 °C for 24 h (Msm) or 14 days (Mtb). On Day 1 (Msm) and Day 
14 (Mtb), Alamar Blue (BUF012B, Celtic Molecular Diagnostics) was added to each well and plates 
were incubated at 37 °C for 6 and 24 h, respectively. Post incubation, the MIC results were visually 
scored and calculated. MIC are defined as the lowest concentration of compound that inhibited visible 
growth. The lowest concentration of drug that prevented the colour change from blue to pink) was 
recorded as the MIC inhibiting >90% of the bacterial population. 
 
6.3.5 In vitro cytotoxicity assay 
The in vitro cytotoxicity of target compounds was tested against mammalian cell-lines (Chinese 
Hamster ovarian (CHO) cells and HepG2 cells) in a 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazoliumbromide (MTT) assay at the Division of Clinical Pharmacology, University of Cape 
Town. The MTT assay is a colorimetric assay used to assess cellular growth and survival.7,8 Reduction 
of the tetrazolium salt MTT to a formazan salt was used to measure all growth and chemosensitivity. 
The final target compounds were tested in triplicate. Stock solutions of the target compounds (20 
mg/mL) were prepared in 10% methanol or 10% DMSO and were used as a suspension if not properly 
dissolved. Final target compounds were stored at -20 ᵒC until further use. Emetine was used as the 
control drug in all experiments. The initial concentration of each compound was 100 μg/mL, which 
was serially diluted in complete medium with 10-fold dilutions to obtain six concentrations, the 
lowest being 0.001 μg/mL. Plates were developed after 44 h exposure to the drug by the addition of 
a solution of MTT. After 4 h incubation at 37 ᵒC, the supernatant was removed via suction and DMSO 
was added to each well to dissolve the reduced dye crystals. The absorbance was measured at a 
wavelength of 540 nm using a spectrophotometer to determine the relative amount of formazan in 
each well. The 50% inhibitory concentration (IC50) values were obtained from full dose-response 
curves via non-linear dose-response curve fitting analysis using GraphPad Prism v.4 software. 
 
6.3.6 In vitro metabolic stability studies 
The metabolic stability of compounds was assessed in mouse, rat, and human liver microsomes at the 
pre-clinical pharmacology laboratory at Groote Schuur Hospital. All compounds were prepared as 10-
mM stock solutions in DMSO. Test compounds (1 μM) were incubated at 37 °C in a solution containing 
0.35 mg/mL microsomes (mouse liver microsomes (MLM), male mouse BALB/c, Xenotech; rat liver 
microsomes (RLM), male rat IGS, Xenotech; human liver microsomes (HLM), mixed gender, Xenotech) 
and NADPH (1 mM) in phosphate buffer (100 mM, pH 7.4) for 30 min while shaking. The samples were 
then precipitated out of solution using cold-ice acetonitrile containing 0.1 μM carbamazepine (internal 
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standard), centrifuged, and filtered for LC-MS analysis. The experiments were performed in triplicate 
and three controls (propranolol, midazolam, and MMV390048) were also included. Results are 
reported as percentage drug remaining unchanged after 30-min incubation and predicted half-life 
estimated using Obach’s formula.  
LC-MS/MS analysis was performed on a 4000 Q-TRAP (AB SCIEX) instrument with a Turbo V® ion 
source coupled to an Agilent 1200 Rapid Resolution (600 bar) HPLC system. ESI mode was used for 
assessment of all synthetic compounds. Analyst 1.5.1 software was used for instrument control and 
data acquisition. Metabolic stability analysis was performed using a Kinetex PFP column (2.1 mm × 50 
mm, 2.6 μm; Phenomenex) or a Kinetex C18 column (2.1 mm × 50 mm, 2.6 μm; Phenomenex) with a 
gradient of 0.4 mL/min (mobile phase A, 0.1% formic acid; B, 0.1% formic acid in acetonitrile) at 40 °C. 
The sample tray temperature was 8 °C and the injection volume used was 2 μL. Multiple reaction 
monitoring (MRM) mode was used for quantification of the parent compound before and after 
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